

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 August 2006 (17.08.2006)

PCT

(10) International Publication Number
WO 2006/084705 A2

(51) International Patent Classification:
C12N 15/11 (2006.01) *C07K 14/705* (2006.01)

(21) International Application Number:
PCT/EP2006/001197

(22) International Filing Date:
10 February 2006 (10.02.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
05405072.9 11 February 2005 (11.02.2005) EP
05405066.1 11 February 2005 (11.02.2005) EP

(71) Applicant (for all designated States except US): **DSM IP ASSETS B.V.** [NL/NL]; Het Overloon 1, NL-6411 TE Heerlen (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHEVREUX, Bastien** [FR/DE]; Katzenbuckelweg 14, 79618 Rheinfelden (DE). **MAYER, Anne, Françoise** [LU/CH]; Rennweg 100, CH-4052 Basel (CH). **MEURY, Anja** [CH/CH]; Breisacherstrasse 12, CH-4057 Basel (CH). **MOUNCEY, Nigel John** [GB/CH]; Curt-Goetz Strasse 18, CH-4102 Binningen (CH). **SHINJOH, Masako** [JP/JP]; 5-5-30 Dai, Kamakura, 247-0061 Kanagawa (JP).

(74) Agents: **SCHWANDER, Kuno, Josef** et al.; c/o DSM Nutritional Products Ltd, Wurmisweg 576, CH-4303 Kaiseraugst (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report
- with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL GENE STS 06

(57) Abstract: The present invention relates to newly identified genes that encode proteins that are involved in the synthesis of L-ascorbic acid (hereinafter also referred to as Vitamin C). The invention also features polynucleotides comprising the full-length polynucleotide sequences of the novel genes and fragments thereof, the novel polypeptides encoded by the polynucleotides and fragments thereof, as well as their functional equivalents. The present invention also relates to the use of said polynucleotides and polypeptides as biotechnological tools in the production of Vitamin C from microorganisms, whereby a modification of said polynucleotides and/or encoded polypeptides has a direct or indirect impact on yield, production, and/or efficiency of production of the fermentation product in said microorganism. Also included are methods/processes of using the polynucleotides and modified polynucleotide sequences to transform host microorganisms. The invention also relates to genetically engineered microorganisms and their use for the direct production of Vitamin C.



WO 2006/084705 A2

Novel Gene STS 06

The present invention relates to newly identified genes that encode proteins that are involved in the synthesis of L-ascorbic acid (hereinafter also referred to as Vitamin C). The invention also features polynucleotides comprising the full-length polynucleotide sequences of the novel genes and fragments thereof, the novel polypeptides encoded by the polynucleotides and fragments thereof, as well as their functional equivalents. The present invention also relates to the use of said polynucleotides and polypeptides as biotechnological tools in the production of Vitamin C from microorganisms, whereby a modification of said polynucleotides and/or encoded polypeptides has a direct or indirect impact on yield, production, and/or efficiency of production of the fermentation product in said microorganism. Also included are methods/processes of using the polynucleotides and modified polynucleotide sequences to transform host microorganisms. The invention also relates to genetically engineered microorganisms and their use for the direct production of Vitamin C.

Vitamin C is one of very important and indispensable nutrient factors for human beings. Vitamin C is also used in animal feed even though some farm animals can synthesize it in their own body.

For the past 70 years, Vitamin C has been produced industrially from D-glucose by the well-known Reichstein method. All steps in this process are chemical except for one (the conversion of D-sorbitol to L-sorbose), which is carried out by microbial conversion. Since its initial implementation for industrial production of Vitamin C, several chemical and technical modifications have been used to improve the efficiency of the Reichstein method. Recent developments of Vitamin C production are summarized in Ullmann's Encyclopedia of Industrial Chemistry, 5th Edition, Vol. A27 (1996), pp. 547ff.

Different intermediate steps of Vitamin C production have been performed with the help of microorganisms or enzymes isolated therefrom. Thus, 2-keto-L-gulonic acid (2-KGA), an intermediate compound that can be chemically converted into Vitamin C by means of an alkaline rearrangement reaction, may be produced by a fermentation process starting from L-sorbose or D-sorbitol, by means of strains belonging *e.g.* to the *Ketogulonicigenium* or *Gluconobacter* genera, or by an alternative fermentation process

starting from D-glucose, by means of recombinant strains belonging to the *Gluconobacter* or *Pantoea* genera.

Current chemical production methods for Vitamin C have some undesirable characteristics such as high-energy consumption and use of large quantities of organic and inorganic solvents. Therefore, over the past decades, other approaches to manufacture Vitamin C using microbial conversions, which would be more economical as well as ecological, have been investigated.

Direct Vitamin C production from a number of substrates including D-sorbitol, L-sorbose and L-sorbose has been reported in several microorganisms, such as algae, yeast and acetic acid bacteria, using different cultivation methods. Examples of known bacteria able to directly produce Vitamin C include, for instance, strains from the genera of *Gluconobacter*, *Gluconacetobacter*, *Acetobacter*, *Ketogulonicigenium*, *Pantoea*, *Pseudomonas* or *Escherichia*. Examples of known yeast or algae include, e.g., *Candida*, *Saccharomyces*, *Zygosaccharomyces*, *Schizosaccharomyces*, *Kluyveromyces* or *Chlorella*.

Microorganisms able to assimilate D-sorbitol for growth usually possess enzymes able to oxidize this compound into a universal assimilation substrate such as D-fructose. Also microorganisms able to grow on L-sorbose possess an enzyme, NAD(P)H-dependent L-sorbose reductase, which is able to reduce this compound to D-sorbitol, which is then further oxidized into D-fructose. D-fructose is an excellent substrate for the growth of many microorganisms, after it has been phosphorylated by means of a D-fructose kinase.

For instance, in the case of acetic acid bacteria, which are obligate aerobe, gram-negative microorganisms belonging to the genus *Acetobacter*, *Gluconobacter*, and *Gluconacetobacter*, these microorganisms are able to transport D-sorbitol into the cytosol and convert it into D-fructose by means of a cytosolic NAD-dependent D-sorbitol dehydrogenase. Some individual strains, such as *Gluconobacter oxydans* IFO 3292, and IFO 3293, are able as well to transport L-sorbose into the cytosol and reduce it to D-sorbitol by means of a cytosolic NAD(P)H-dependent L-sorbose reductase, which then is further oxidized into D-fructose. In these bacteria, the Embden-Meyerhof-Parnas pathway, as well as the tricarboxylic acid cycle are not fully active, and the main pathway channeling sugars into the central metabolism is the pentose phosphate pathway. D-fructose-6-phosphate, obtained from D-fructose by a phosphorylation reaction enters the pentose phosphate pathway, being further metabolized and producing reducing power in the form of NAD(P)H and tricarboxylic compounds necessary for growth and maintenance.

Acetic acid bacteria are well known for their ability to incompletely oxidize different substrates such as alcohols, sugars, sugar alcohols and aldehydes. These processes are generally known as oxidative fermentations or incomplete oxidations, and they have been well established for a long time in the food and chemical industry, especially in vinegar
5 and in L-sorbose production. A useful product known to be obtained from incomplete oxidations of D-sorbitol or L-sorbose using strains belonging to the *Gluconobacter* genus is 2-KGA.

Acetic acid bacteria accomplish these incomplete oxidation reactions by means of different dehydrogenases located either in the periplasmic space, on the periplasmic membrane as
10 well as in the cytoplasm. Different co-factors are employed by the different dehydrogenases, the most common being PQQ and FAD for membrane-bound or periplasmic enzymes, and NAD/NADP for cytoplasmic enzymes.

While all products of these oxidation reactions diffuse back to the external aqueous environment through the outer membrane, some of them can be passively or actively
15 transported into the cell and be further used in metabolic pathways responsible for growth and energy formation. Inside the cell, oxidized products can many times be reduced back to their original substrate by means of reductases, and then be channeled back to the central metabolism.

Proteins, in particular transporters, that are active in the transportation of sugar such as *e.g.*
20 glucose, sugar alcohols and related compounds across the cellular membrane are herein referred to as being involved in the Sugar Transport System. Such proteins are abbreviated herein as STS proteins.

STS proteins are in general membrane-bound or are associated to membrane-bound structures and are functional as single proteins or as subunits in protein complexes such as
25 permeases or active transporters. STS proteins are known to be responsible for selectively facilitating, assisting or enabling the transport of compounds such as sugars, sugar alcohols, sugar ketones or sugar aldehydes across the cellular or periplasmic membrane.

STS proteins can be divided into three types on the basis of their mechanisms. The first class of transporters uses energy from the proton-motive force to transport molecules
30 against a concentration gradient. These symport and antiport systems couple the movement of two different molecules across the membrane (via permeases having two separate binding sites for the two different molecules); in symport, both molecules are transported in the same direction, while in antiport, one molecule is imported while the other is exported.

The second class of transporters, the phosphotransferase system (PTS), is energized by the transfer of a high-energy phosphate group from phosphoenolpyruvate, through various protein components, to the substrate which is phosphorylated upon import as its phosphoester form.

- 5 The third class of transporters couples the hydrolysis of ATP to substrate translocation. These systems are termed the ATP-binding cassette (ABC) type transporters. The ABC-transport system consists of a substrate specific binding protein which is located in the periplasm in gram-negative bacteria or which is membrane associated in gram-positive bacteria, an integral membrane domain and a cytoplasmic-facing ATP hydrolyzing
10 domain.

- A more detailed description of membrane transport systems can be found in: Bamberg, E. et al (1993) "Charge transport of ion pumps on lipid bilayer membranes", Q. Rev. Biophys. 26:1-25; Findlay, J.B.C. (1991) "Structure and function of membrane transport systems", Curr. Opin. Struct. Biol. 1:804-810; Higgins, C.F. (1992) "ABC transporters
15 from microorganism to man" Ann. Rev. Cell Biol. 8:67-113; Gennis, R.B. (1989) "Pores, channels and transporters" in: Biomembranes, Molecular Structure and Function, Springer, Heidelberg, p. 270-322; Nikaido, H. & Saier H. (1992) "Transport proteins in bacteria: common themes in their design" Science 258:936-942.

- An object of the present invention is to improve the yields and or productivity of Vitamin
20 C production.

Surprisingly, it has now been found that STS proteins or subunits of such proteins having activity towards or which are involved in the transportation of compounds across cellular membranes play an important role in the biotechnological production of Vitamin C.

- In one embodiment, STS proteins of the present invention are selected from transferases
25 [EC 2], preferably PTS proteins and/or subunits thereof [EC 2.7], more preferably phosphotransferases with an alcohol group as acceptor [EC 2.7.1] and phosphotransferases with a nitrogenous group as acceptor [EC 2.7.3], most preferably protein-*np*-phosphohistidine-sugar phosphotransferase [EC 2.7.1.69] and phosphoenolpyruvate-protein phosphotransferase [EC 2.7.3.9] or from hydrolases [EC 3], preferably hydrolases
30 acting on acid anhydrides [EC 3.6].

- Furthermore, the STS proteins of the present invention may be selected from sugar transporters and/or sugar alcohol transporters, preferably transporter proteins and periplasmic binding/transfer proteins, more preferably, periplasmic sorbitol-binding proteins, periplasmic solute-binding proteins, periplasmic D-allose-binding proteins,
35 trehalose/maltose ABC transporters including subunits like membrane components,

- 5 -

mannitol/sorbitol ABC-type transporter including subunits like MtlK ATPase or membrane (MtlG or MtlF) components, and proteins involved in PTS including PtsI enzyme I, Hpr protein, enzyme IIA^{Man}, P-loop ATPase protein family or Hpr kinases.

In particular, it has now been found that STS proteins encoded by polynucleotides having
5 a nucleotide sequence that hybridizes preferably under highly stringent conditions to a sequence shown in SEQ ID NO:1 play an important role in the biotechnological production of Vitamin C. It has also been found, that by genetically altering the expression level of nucleotides according to the invention in a microorganism capable of directly producing Vitamin C, such as for example *Gluconobacter*, the direct fermentation
10 of Vitamin C by said microorganism can be even greatly improved.

Consequently, the invention relates to a polynucleotide selected from the group consisting of:

- (a) polynucleotides encoding a polypeptide comprising the amino acid sequence according to SEQ ID NO:2;
- 15 (b) polynucleotides comprising the nucleotide sequence according to SEQ ID NO:1;
- (c) polynucleotides comprising a nucleotide sequence obtainable by nucleic acid amplification such as polymerase chain reaction, using genomic DNA from a microorganism as a template and a primer set according to SEQ ID NO:3 and SEQ ID NO:4;
- 20 (d) polynucleotides comprising a nucleotide sequence encoding a fragment or derivative of a polypeptide encoded by a polynucleotide of any of (a) to (c) wherein in said derivative one or more amino acid residues are conservatively substituted compared to said polypeptide, and said fragment or derivative has the activity of a sugar transporter and/or sugar alcohol transporter, preferably STS 06 activity;
- 25 (e) polynucleotides the complementary strand of which hybridizes under stringent conditions to a polynucleotide as defined in any one of (a) to (d) and which encode a sugar transporter and/or sugar alcohol transporter, preferably a STS 06 polypeptide; and
- (f) polynucleotides which are at least 70%, such as 85, 90 or 95% identical to a polynucleotide as defined in any one of (a) to (d) and which encode a sugar transporter
30 and/or sugar alcohol transporter, preferably a STS 06 polypeptide;

or

the complementary strand of such a polynucleotide.

- 6 -

The STS protein as isolated from *Gluconobacter oxydans* DSM 17078 shown in SEQ ID NO:2 and described herein was found to be a particularly useful STS protein, since it appeared that it performs a crucial function in the direct Vitamin C production in microorganisms, in particular in bacteria, such as acetic acid bacteria, such as

5 *Gluconobacter*, *Acetobacter* and *Gluconacetobacter*. Accordingly, the invention relates to a polynucleotide encoding a polypeptide according to SEQ ID NO:2. This protein may be encoded by a nucleotide sequence as shown in SEQ ID NO:1. The invention therefore also relates to polynucleotides comprising the nucleotide sequence according to SEQ ID NO:1.

10 The nucleotide and amino acid sequences determined above were used as a "query sequence" to perform a search with Blast2 program (version 2 or BLAST from National Center for Biotechnology [NCBI] against the database PRO SW-SwissProt (full release plus incremental updates). From the searches, the STS 06 polynucleotide according to SEQ ID NO:1 was annotated as encoding a membrane component of the trehalose/maltose
15 ABC-type transporter.

A nucleic acid according to the invention may be obtained by nucleic acid amplification using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers such as the nucleotide primers according to SEQ ID NO:3 and SEQ ID NO:4 according to standard PCR amplification techniques. The nucleic acid thus
20 amplified may be cloned into an appropriate vector and characterized by DNA sequence analysis.

The template for the reaction may be cDNA obtained by reverse transcription of mRNA prepared from strains known or suspected to comprise a polynucleotide according to the invention. The PCR product may be subcloned and sequenced to ensure that the amplified
25 sequences represent the sequences of a new nucleic acid sequence as described herein, or a functional equivalent thereof.

The PCR fragment may then be used to isolate a full length cDNA clone by a variety of known methods. For example, the amplified fragment may be labeled and used to screen a bacteriophage or cosmid cDNA library. Alternatively, the labeled fragment may be used
30 to screen a genomic library.

Accordingly, the invention relates to polynucleotides comprising a nucleotide sequence obtainable by nucleic acid amplification such as polymerase chain reaction, using DNA such as genomic DNA from a microorganism as a template and a primer set according to SEQ ID NO:3 and SEQ ID NO:4.

The invention also relates to polynucleotides comprising a nucleotide sequence encoding a fragment or derivative of a polypeptide encoded by a polynucleotide as described herein wherein in said derivative one or more amino acid residues are conservatively substituted compared to said polypeptide, and said fragment or derivative has the activity of a STS polypeptide, preferably a STS 06 polypeptide.

The invention also relates to polynucleotides the complementary strand of which hybridizes under stringent conditions to a polynucleotide as defined herein and which encode a STS polypeptide, preferably a STS 06 polypeptide.

The invention also relates to polynucleotides which are at least 70% identical to a polynucleotide as defined herein and which encode a STS polypeptide; and the invention also relates to polynucleotides being the complementary strand of a polynucleotide as defined herein above.

The invention also relates to microorganisms wherein the activity of a STS polypeptide, preferably a STS 06 polypeptide, is reduced or abolished so that the yield of Vitamin C which is directly produced from D-sorbitol or L-sorbose is increased.

The skilled person will know how to reduce or abolish the activity of a STS protein, preferably a STS 06 protein. Such may be for instance accomplished by either genetically modifying the host organism in such a way that it produces less or no copies of the STS protein, preferably the STS 06 protein, than the wild type organism or by decreasing or abolishing the specific activity of the STS protein, preferably the STS 06 protein.

In the following description, procedures are detailed to achieve this goal, *i.e.* the increase in the yield and/or production of Vitamin C which is directly produced from D-sorbitol or L-sorbose by reducing or abolishing the activity of a STS 06 protein. These procedures apply *mutatis mutandis* for other STS proteins.

Modifications in order to have the organism produce less or no copies of the STS 06 gene and/or protein may include the use of a weak promoter, or the mutation (*e.g.* insertion, deletion or point mutation) of (parts of) the STS 06 gene or its regulatory elements. Decreasing or abolishing the specific activity of a STS 06 protein may also be accomplished by methods known in the art. Such methods may include the mutation (*e.g.* insertion, deletion or point mutation) of (parts of) the STS 06 gene.

Also known in the art are methods of reducing or abolishing the activity of a given protein by contacting the STS 06 protein with specific inhibitors or other substances that specifically interact with the STS 06 protein. In order to identify such specific inhibitors, the STS 06 protein may be expressed and tested for activity in the presence of compounds

suspected to inhibit the activity of the STS 06 protein. Potential inhibiting compounds may for instance be monoclonal or polyclonal antibodies against the STS 06 protein. Such antibodies may be obtained by routine immunization protocols of suitable laboratory animals.

- 5 The invention may be performed in any microorganism carrying a STS 06 gene or homologue thereof. Suitable microorganisms may be selected from the group consisting of yeast, algae and bacteria, either as wild type strains, mutant strains derived by classic mutagenesis and selection methods or as recombinant strains. Examples of such yeast may be, e.g., *Candida*, *Saccharomyces*, *Zygosaccharomyces*, *Schizosaccharomyces*, or
- 10 *Kluyveromyces*. An example of such algae may be, e.g., *Chlorella*. Examples of such bacteria may be, e.g., *Gluconobacter*, *Acetobacter*, *Gluconacetobacter*, *Ketogulonicigenium*, *Pantoea*, *Pseudomonas*, such as, e.g., *Pseudomonas putida*, and *Escherichia*, such as, e.g., *Escherichia coli*. Preferred are *Gluconobacter* or *Acetobacter aceti*, such as for instance *G. oxydans*, *G. cerinus*, *G. frateurii*, *A. aceti subsp. xylinum* or
- 15 *A. aceti subsp. orleanus*, preferably *G. oxydans* DSM 17078. *Gluconobacter oxydans* DSM 17078 (formerly known as *Gluconobacter oxydans* N44-1) has been deposited at Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ), Mascheroder Weg 1B, D-38124 Braunschweig, Germany according to the Budapest Treaty on 26. January 2005.
- 20 Microorganisms which can be used for the present invention may be publicly available from different sources, e.g., Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ), Mascheroder Weg 1B, D-38124 Braunschweig, Germany, American Type Culture Collection (ATCC), P.O. Box 1549, Manassas, VA 20108 USA or Culture Collection Division, NITE Biological Resource Center, 2-5-8, Kazusakamatari, Kisarazu-
- 25 shi, Chiba, 292-0818, Japan (formerly: Institute for Fermentation, Osaka (IFO), 17-85, Juso-honmachi 2-chome, Yodogawa-ku, Osaka 532-8686, Japan). Examples of preferred bacteria deposited with IFO are for instance *Gluconobacter oxydans* (formerly known as *G. melanogenus*) IFO 3293, *Gluconobacter oxydans* (formerly known as *G. melanogenus*) IFO 3292, *Gluconobacter oxydans* (formerly known as *G. rubiginosus*) IFO 3244,
- 30 *Gluconobacter frateurii* (formerly known as *G. industrius*) IFO 3260, *Gluconobacter cerinus* IFO 3266, *Gluconobacter oxydans* IFO 3287, and *Acetobacter aceti subsp. orleanus* IFO 3259, which were all deposited on April 05, 1954; *Acetobacter aceti subsp. xylinum* IFO 13693 deposited on October 22, 1975, and *Acetobacter aceti subsp. xylinum* IFO 13773 deposited on December 08, 1977. Strain *Acetobacter sp.* ATCC 15164, which
- 35 is also an example of a preferred bacterium, was deposited with ATCC. Strain *Gluconobacter oxydans* (formerly known as *G. melanogenus*) N 44-1 as another example

of a preferred bacterium is a derivative of the strain IFO 3293 and is described in Sugisawa et al., Agric. Biol. Chem. 54: 1201-1209, 1990.

A microorganism as of the present invention may carry further modifications either on the DNA or protein level (see above), as long as such modification has a direct impact on the yield, production and/or efficiency of the direct production of Vitamin C from substrates like *e.g.* D-sorbitol or L-sorbose. Such further modifications may for instance affect other genes encoding STS proteins as described above, in particular genes encoding membrane-bound L-sorbose dehydrogenases, such as L-sorbose dehydrogenase SNDHai, or membrane-bound PQQ bound D-sorbitol dehydrogenases. Methods of performing such modifications are known in the art, with some examples further described herein. For the use of SNDHai for direct production of vitamin C as well as the nucleotide and amino acid sequence thereof we refer to WO 2005/017159 which is incorporated herein by reference.

In accordance with a further object of the present invention there is provided the use of a polynucleotide as defined above or a microorganism which is genetically engineered using such polynucleotides in the production of Vitamin C.

The invention also relates to processes for the expression of endogenous genes in a microorganism, to processes for the production of polypeptides as defined above in a microorganism and to processes for the production of microorganisms capable of producing Vitamin C. All these processes may comprise the step of altering a microorganism, wherein "altering" as used herein encompasses the process for "genetically altering" or "altering the composition of the cell culture media and/or methods used for culturing" in such a way that the yield and/or productivity of the fermentation product can be improved compared to the wild-type organism. As used herein, "improved yield of Vitamin C" means an increase of at least 5%, 10%, 25%, 30%, 40%, 50%, 75%, 100%, 200% or even more than 500%, compared to a wild-type microorganism, *i.e.* a microorganism which is not genetically altered.

The term "genetically engineered" or "genetically altered" means the scientific alteration of the structure of genetic material in a living organism. It involves the production and use of recombinant DNA. More in particular it is used to delineate the genetically engineered or modified organism from the naturally occurring organism. Genetic engineering may be done by a number of techniques known in the art, such as *e.g.* gene replacement, gene amplification, gene disruption, transfection, transformation using plasmids, viruses, or other vectors. A genetically modified organism, *e.g.* genetically modified microorganism, is also often referred to as a recombinant organism, *e.g.* recombinant microorganism.

In accordance with still another aspect of the invention there is provided a process for the production of Vitamin C by direct fermentation.

In particular, the present invention provides a process for the direct production of Vitamin C comprising converting a substrate into Vitamin C. This may for instance be done in a medium comprising a microorganism, which may be a resting or a growing
5 microorganism, preferably a resting microorganism.

Several substrates may be used as a carbon source in a process of the present invention, *i.e.* a process for direct conversion of a given substrate into Vitamin C such as *e.g.* mentioned above. Particularly suited carbon sources are those that are easily obtainable from the D-glucose or D-sorbitol metabolization pathway such as, for example, D-glucose, D-sorbitol,
10 L-sorbose, L-sorbosone, 2-keto-L-gulonate, D-gluconate, 2-keto-D-gluconate or 2,5-diketo-gluconate. Preferably, the substrate is selected from for instance D-glucose, D-sorbitol, L-sorbose or L-sorbosone, more preferably from D-glucose, D-sorbitol or L-sorbose, and most preferably from D-sorbitol, L-sorbose or L-sorbosone. The term
15 "substrate" and "production substrate" in connection with the above process using a microorganism is used interchangeably herein.

A medium as used herein for the above process using a microorganism may be any suitable medium for the production of Vitamin C. Typically, the medium is an aqueous medium comprising for instance salts, substrate(s), and a certain pH. The medium in
20 which the substrate is converted into Vitamin C is also referred to as the production medium.

"Fermentation" or "production" or "fermentation process" as used herein may be the use of growing cells using media, conditions and procedures known to the skilled person, or the use of non-growing so-called resting cells, after they have been cultivated by using media,
25 conditions and procedures known to the skilled person, under appropriate conditions for the conversion of suitable substrates into desired products such as Vitamin C. Preferably, resting cells are used for the production of Vitamin C.

The term "direct fermentation", "direct production", "direct conversion" and the like is intended to mean that a microorganism is capable of the conversion of a certain substrate
30 into the specified product by means of one or more biological conversion steps, without the need of any additional chemical conversion step. For instance, the term "direct conversion of D-sorbitol into Vitamin C" is intended to describe a process wherein a microorganism is producing Vitamin C and wherein D-sorbitol is offered as a carbon source without the need of an intermediate chemical conversion step. A single
35 microorganism capable of directly fermenting Vitamin C is preferred. Said microorganism

is cultured under conditions which allow such conversion from the substrate as defined above.

In connection with the above process using a microorganism it is understood that the above-mentioned microorganisms also include synonyms or basonyms of such species
5 having the same physiological properties, as defined by the International Code of Nomenclature of Prokaryotes. The nomenclature of the microorganisms as used herein is the one officially accepted (at the filing date of the priority application) by the International Committee on Systematics of Prokaryotes and the Bacteriology and Applied Microbiology Division of the International Union of Microbiological Societies, and
10 published by its official publication vehicle International Journal of Systematic and Evolutionary Microbiology (IJSEM). A particular reference is made to Urbance et al., IJSEM (2001) vol 51:1059-1070, with a corrective notification on IJSEM (2001) vol 51:1231-1233, describing the taxonomically reclassification of *G. oxydans* DSM 4025 as *Ketogulonicigenium vulgare*.

15 As used herein, resting cells refer to cells of a microorganism which are for instance viable but not actively growing, or which are growing at low specific growth rates, for instance, growth rates that are lower than 0.02 h^{-1} , preferably lower than 0.01 h^{-1} . Cells which show the above growth rates are said to be in a "resting cell mode".

The process of the present invention as above using a microorganism may be performed in
20 different steps or phases: preferably, the microorganism is cultured in a first step (also referred to as step (a) or growth phase) under conditions which enable growth. This phase is terminated by changing of the conditions such that the growth rate of the microorganism is reduced leading to resting cells, also referred to as step (b), followed by the production of Vitamin C from the substrate using the (b), also referred to as production phase.

25 Growth and production phase as performed in the above process using a microorganism may be performed in the same vessel, *i.e.*, only one vessel, or in two or more different vessels, with an optional cell separation step between the two phases. The produced Vitamin C can be recovered from the cells by any suitable means. Recovering means for instance that the produced Vitamin C may be separated from the production medium.

30 Optionally, the thus produced Vitamin C may be further processed.

For the purpose of the present invention relating to the above process using a microorganism, the terms "growth phase", "growing step", "growth step" and "growth period" are used interchangeably herein. The same applies for the terms "production phase", "production step", "production period".

One way of performing the above process using a microorganism as of the present invention may be a process wherein the microorganism is grown in a first vessel, the so-called growth vessel, as a source for the resting cells, and at least part of the cells are transferred to a second vessel, the so-called production vessel. The conditions in the
5 production vessel may be such that the cells transferred from the growth vessel become resting cells as defined above. Vitamin C is produced in the second vessel and recovered therefrom.

In connection with the above process using a microorganism, in one aspect, the growing step can be performed in an aqueous medium, *i.e.* the growth medium, supplemented with
10 appropriate nutrients for growth under aerobic conditions. The cultivation may be conducted, for instance, in batch, fed-batch, semi-continuous or continuous mode. The cultivation period may vary depending on for instance the host, pH, temperature and nutrient medium to be used, and may be for instance about 10 h to about 10 days, preferably about 1 to about 10 days, more preferably about 1 to about 5 days when run in
15 batch or fed-batch mode, depending on the microorganism. If the cells are grown in continuous mode, the residence time may be for instance from about 2 to about 100 h, preferably from about 2 to about 50 h, depending on the microorganism. If the microorganism is selected from bacteria, the cultivation may be conducted for instance at a pH of about 3.0 to about 9.0, preferably about 4.0 to about 9.0, more preferably about 4.0
20 to about 8.0, even more preferably about 5.0 to about 8.0. If algae or yeast are used, the cultivation may be conducted, for instance, at a pH below about 7.0, preferably below about 6.0, more preferably below about 5.5, and most preferably below about 5.0. A suitable temperature range for carrying out the cultivation using bacteria may be for instance from about 13°C to about 40°C, preferably from about 18°C to about 37°C, more
25 preferably from about 13°C to about 36°C, and most preferably from about 18°C to about 33°C. If algae or yeast are used, a suitable temperature range for carrying out the cultivation may be for instance from about 15°C to about 40°C, preferably from about 20°C to about 45°C, more preferably from about 25°C to about 40°C, even more preferably from about 25°C to about 38°C, and most preferably from about 30°C to about
30 38°C. The culture medium for growth usually may contain such nutrients as assimilable carbon sources, *e.g.*, glycerol, D-mannitol, D-sorbitol, L-sorbose, erythritol, ribitol, xylitol, arabitol, inositol, dulcitol, D-ribose, D-fructose, D-glucose, sucrose, and ethanol, preferably L-sorbose, D-glucose, D-sorbitol, D-mannitol, glycerol and ethanol; and digestible nitrogen sources such as organic substances, *e.g.*, peptone, yeast extract and
35 amino acids. The media may be with or without urea and/or corn steep liquor and/or baker's yeast. Various inorganic substances may also be used as nitrogen sources, *e.g.*, nitrates and ammonium salts. Furthermore, the growth medium, usually may contain inorganic salts, *e.g.*, magnesium sulfate, manganese sulfate, potassium phosphate, and

calcium carbonate. Cells obtained using the procedures described above can then be further incubated at essentially the same modes, temperature and pH conditions as described above, in the presence of substrates such as D-sorbitol, L-sorbose, or D-glucose, in such a way that they convert these substrates directly into Vitamin C. Incubation can be
5 done in a nitrogen-rich medium, containing, for example, organic nitrogen sources, *e.g.*, peptone, yeast extract, baker's yeast, urea, amino acids, and corn steep liquor, or inorganic nitrogen sources, *e.g.*, nitrates and ammonium salts, in which case cells will be able to further grow while producing Vitamin C. Alternatively, incubation can be done in a nitrogen-poor medium, in which case cells will not grow substantially, and will be in a
10 resting cell mode, or biotransformation mode. In all cases, the incubation medium may also contain inorganic salts, *e.g.*, magnesium sulfate, manganese sulfate, potassium phosphate, and calcium chloride.

In connection with the above process using a microorganism, in the growth phase the specific growth rates are for instance at least 0.02 h^{-1} . For cells growing in batch, fed-
15 batch or semi-continuous mode, the growth rate depends on for instance the composition of the growth medium, pH, temperature, and the like. In general, the growth rates may be for instance in a range from about 0.05 h^{-1} to about 0.2 h^{-1} , preferably from about 0.06 to about 0.15 h^{-1} , and most preferably from about 0.07 to about 0.13 h^{-1} .

In another aspect of the above process using a microorganism, resting cells may be
20 provided by cultivation of the respective microorganism on agar plates thus serving as growth vessel, using essentially the same conditions, *e.g.*, cultivation period, pH, temperature, nutrient medium as described above, with the addition of agar agar.

In connection with the above process using a microorganism, if the growth and production phase are performed in two separate vessels, then the cells from the growth phase may be
25 harvested or concentrated and transferred to a second vessel, the so-called production vessel. This vessel may contain an aqueous medium supplemented with any applicable production substrate that can be converted to Vitamin C by the cells. Cells from the growth vessel can be harvested or concentrated by any suitable operation, such as for instance centrifugation, membrane crossflow ultrafiltration or microfiltration, filtration,
30 decantation, flocculation. The cells thus obtained may also be transferred to the production vessel in the form of the original broth from the growth vessel, without being harvested, concentrated or washed, *i.e.* in the form of a cell suspension. In a preferred embodiment, the cells are transferred from the growth vessel to the production vessel in the form of a cell suspension without any washing or isolating step in-between.

Thus, in a preferred embodiment of the above process using a microorganism step (a) and (c) of the process of the present invention as described above are not separated by any washing and/or separation step.

In connection with the above process using a microorganism, if the growth and production
5 phase are performed in the same vessel, cells may be grown under appropriate conditions to the desired cell density followed by a replacement of the growth medium with the production medium containing the production substrate. Such replacement may be, for instance, the feeding of production medium to the vessel at the same time and rate as the withdrawal or harvesting of supernatant from the vessel. To keep the resting cells in the
10 vessel, operations for cell recycling or retention may be used, such as for instance cell recycling steps. Such recycling steps, for instance, include but are not limited to methods using centrifuges, filters, membrane crossflow microfiltration or ultrafiltration steps, membrane reactors, flocculation, or cell immobilization in appropriate porous, non-porous or polymeric matrixes. After a transition phase, the vessel is brought to process conditions
15 under which the cells are in a resting cell mode as defined above, and the production substrate is efficiently converted into Vitamin C.

The aqueous medium in the production vessel as used for the production step in connection with the above process using a microorganism, hereinafter called production medium, may contain only the production substrate(s) to be converted into Vitamin C, or
20 may contain for instance additional inorganic salts, *e.g.*, sodium chloride, calcium chloride, magnesium sulfate, manganese sulfate, potassium phosphate, calcium phosphate, and calcium carbonate. The production medium may also contain digestible nitrogen sources such as for instance organic substances, *e.g.*, peptone, yeast extract, urea, amino acids, and corn steep liquor, and inorganic substances, *e.g.* ammonia, ammonium sulfate,
25 and sodium nitrate, at such concentrations that the cells are kept in a resting cell mode as defined above. The medium may be with or without urea and/or corn steep liquor and/or baker's yeast. The production step may be conducted for instance in batch, fed-batch, semi-continuous or continuous mode. In case of fed-batch, semi-continuous or continuous mode, both cells from the growth vessel and production medium can be fed continuously
30 or intermittently to the production vessel at appropriate feed rates. Alternatively, only production medium may be fed continuously or intermittently to the production vessel, while the cells coming from the growth vessel are transferred at once to the production vessel. The cells coming from the growth vessel may be used as a cell suspension within the production vessel or may be used as for instance flocculated or immobilized cells in
35 any solid phase such as porous or polymeric matrixes. The production period, defined as the period elapsed between the entrance of the substrate into the production vessel and the harvest of the supernatant containing Vitamin C, the so-called harvest stream, can vary

depending for instance on the kind and concentration of cells, pH, temperature and nutrient medium to be used, and is preferably about 2 to about 100 h. The pH and temperature can be different from the pH and temperature of the growth step, but is essentially the same as for the growth step.

- 5 In a preferred embodiment of the above process using a microorganism, the production step is conducted in continuous mode, meaning that a first feed stream containing the cells from the growth vessel and a second feed stream containing the substrate is fed continuously or intermittently to the production vessel. The first stream may either contain only the cells isolated/separated from the growth medium or a cell suspension, coming
- 10 directly from the growth step, *i.e.* cells suspended in growth medium, without any intermediate step of cell separation, washing and/or isolating. The second feed stream as herein defined may include all other feed streams necessary for the operation of the production step, *e.g.* the production medium comprising the substrate in the form of one or several different streams, water for dilution, and base for pH control.
- 15 In connection with the above process using a microorganism, when both streams are fed continuously, the ratio of the feed rate of the first stream to feed rate of the second stream may vary between about 0.01 and about 10, preferably between about 0.01 and about 5, most preferably between about 0.02 and about 2. This ratio is dependent on the concentration of cells and substrate in the first and second stream, respectively.
- 20 Another way of performing the process as above using a microorganism of the present invention may be a process using a certain cell density of resting cells in the production vessel. The cell density is measured as absorbance units (optical density) at 600 nm by methods known to the skilled person. In a preferred embodiment, the cell density in the production step is at least about 10, more preferably between about 10 and about 200, even
- 25 more preferably between about 15 and about 200, even more preferably between about 15 to about 120, and most preferably between about 20 and about 120.

- In connection with the above process using a microorganism, in order to keep the cells in the production vessel at the desired cell density during the production phase as performed, for instance, in continuous or semi-continuous mode, any means known in the art may be
- 30 used, such as for instance cell recycling by centrifugation, filtration, membrane crossflow ultrafiltration of microfiltration, decantation, flocculation, cell retention in the vessel by membrane devices or cell immobilization. Further, in case the production step is performed in continuous or semi-continuous mode and cells are continuously or intermittently fed from the growth vessel, the cell density in the production vessel may be
- 35 kept at a constant level by, for instance, harvesting an amount of cells from the production vessel corresponding to the amount of cells being fed from the growth vessel.

In connection with the above process using a microorganism, the produced Vitamin C contained in the so-called harvest stream is recovered/harvested from the production vessel. The harvest stream may include, for instance, cell-free or cell-containing aqueous solution coming from the production vessel, which contains Vitamin C as a result of the
5 conversion of production substrate by the resting cells in the production vessel. Cells still present in the harvest stream may be separated from the Vitamin C by any operations known in the art, such as for instance filtration, centrifugation, decantation, membrane crossflow ultrafiltration or microfiltration, tangential flow ultrafiltration or microfiltration or dead end filtration. After this cell separation operation, the harvest stream is essentially
10 free of cells.

In a further aspect, the process of the present invention may be combined with further steps of separation and/or purification of the produced Vitamin C from other components contained in the harvest stream, *i.e.*, so-called downstream processing steps. These steps may include any means known to a skilled person, such as, for instance, concentration,
15 crystallization, precipitation, adsorption, ion exchange, electrodialysis, bipolar membrane electrodialysis and/or reverse osmosis. Vitamin C may be further purified as the free acid form or any of its known salt forms by means of operations such as for instance treatment with activated carbon, ion exchange, adsorption and elution, concentration, crystallization, filtration and drying. Specifically, a first separation of Vitamin C from other components
20 in the harvest stream might be performed by any suitable combination or repetition of, for instance, the following methods: two- or three-compartment electrodialysis, bipolar membrane electrodialysis, reverse osmosis or adsorption on, for instance, ion exchange resins or non-ionic resins. If the resulting form of Vitamin C is a salt of L-ascorbic acid, conversion of the salt form into the free acid form may be performed by for instance
25 bipolar membrane electrodialysis, ion exchange, simulated moving bed chromatographic techniques, and the like. Combination of the mentioned steps, *e.g.*, electrodialysis and bipolar membrane electrodialysis into one step might be also used as well as combination of the mentioned steps *e.g.* several steps of ion exchange by using simulated moving bed chromatographic methods. Any of these procedures alone or in combination constitute a
30 convenient means for isolating and purifying the product, *i.e.* Vitamin C. The product thus obtained may further be isolated in a manner such as, *e.g.* by concentration, crystallization, precipitation, washing and drying of the crystals and/or further purified by, for instance, treatment with activated carbon, ion exchange and/or re-crystallization.

In a preferred embodiment, Vitamin C is purified from the harvest stream by a series of
35 downstream processing steps as described above without having to be transferred to a non-aqueous solution at any time of this processing, *i.e.* all steps are performed in an aqueous environment. Such preferred downstream processing procedure may include for instance

the concentration of the harvest stream coming from the production vessel by means of two- or three-compartment electrodialysis, conversion of Vitamin C in its salt form present in the concentrated solution into its acid form by means of bipolar membrane electrodialysis and/or ion exchange, purification by methods such as for instance treatment
5 with activated carbon, ion exchange or non-ionic resins, followed by a further concentration step and crystallization. These crystals can be separated, washed and dried. If necessary, the crystals may be again re-solubilized in water, treated with activated carbon and/or ion exchange resins and recrystallized. These crystals can then be separated, washed and dried.

10 Advantageous embodiments of the invention become evident from the dependent claims. These and other aspects and embodiments of the present invention should be apparent to those skilled in the art from the teachings herein.

The sequence of the gene comprising a nucleotide sequence according to SEQ ID NO:1 encoding a STS 06 protein was determined by sequencing a genomic clone obtained from
15 *Gluconobacter oxydans* DSM 17078.

The invention also relates to a polynucleotide encoding at least a biologically active fragment or derivative of a STS 06 polypeptide as shown in SEQ ID NO:2.

As used herein, "biologically active fragment or derivative" means a polypeptide which retains essentially the same biological function or activity as the polypeptide shown in
20 SEQ ID NO:2. Examples of biological activity may for instance be enzymatic activity, signaling activity or antibody reactivity. The term "same biological function" or "functional equivalent" as used herein means that the protein has essentially the same biological activity, *e.g.* enzymatic, signaling or antibody reactivity, as a polypeptide shown in SEQ ID NO:2.

25 The polypeptides and polynucleotides of the present invention are preferably provided in an isolated form, and preferably are purified to homogeneity.

The term "isolated" means that the material is removed from its original environment (*e.g.*, the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living microorganism is not isolated, but the
30 same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition and still be isolated in that such vector or composition is not part of its natural environment.

An isolated polynucleotide or nucleic acid as used herein may be a DNA or RNA that is not immediately contiguous with both of the coding sequences with which it is immediately contiguous (one on the 5'-end and one on the 3'-end) in the naturally occurring genome of the organism from which it is derived. Thus, in one embodiment, a nucleic acid includes some or all of the 5'-non-coding (*e.g.*, promoter) sequences that are immediately contiguous to the coding sequence. The term "isolated polynucleotide" therefore includes, for example, a recombinant DNA that is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (*e.g.*, a cDNA or a genomic DNA fragment produced by PCR or restriction endonuclease treatment) independent of other sequences. It also includes a recombinant DNA that is part of a hybrid gene encoding an additional polypeptide that is substantially free of cellular material, viral material, or culture medium (when produced by recombinant DNA techniques), or chemical precursors or other chemicals (when chemically synthesized). Moreover, an "isolated nucleic acid fragment" is a nucleic acid fragment that is not naturally occurring as a fragment and would not be found in the natural state.

As used herein, the terms "polynucleotide", "gene" and "recombinant gene" refer to nucleic acid molecules which may be isolated from chromosomal DNA, which include an open reading frame encoding a protein, *e.g.* *G. oxydans* DSM 17078 STS proteins. A polynucleotide may include a polynucleotide sequence as shown in SEQ ID NO:1 or fragments thereof and regions upstream and downstream of the gene sequences which may include, for example, promoter regions, regulator regions and terminator regions important for the appropriate expression and stabilization of the polypeptide derived thereof.

A gene may include coding sequences, non-coding sequences such as for instance untranslated sequences located at the 3'- and 5'-ends of the coding region of a gene, and regulatory sequences. Moreover, a gene refers to an isolated nucleic acid molecule as defined herein. It is furthermore appreciated by the skilled person that DNA sequence polymorphisms that lead to changes in the amino acid sequences of STS proteins may exist within a population, *e.g.*, the *Gluconobacter oxydans* population. Such genetic polymorphism in the STS 06 gene may exist among individuals within a population due to natural variation or in cells from different populations. Such natural variations can typically result in 1-5% variance in the nucleotide sequence of the STS 06 gene. Any and all such nucleotide variations and the resulting amino acid polymorphism in STS 06 are the result of natural variation and that do not alter the functional activity of STS proteins are intended to be within the scope of the invention.

As used herein, the terms "polynucleotide" or "nucleic acid molecule" are intended to include DNA molecules (*e.g.*, cDNA or genomic DNA) and RNA molecules (*e.g.*, mRNA)

and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule may be single-stranded or double-stranded, but preferably is double-stranded DNA. The nucleic acid may be synthesized using oligonucleotide analogs or derivatives (e.g., inosine or phosphorothioate-nucleotides). Such oligonucleotides may be used, for example, to prepare nucleic acids that have altered base-pairing abilities or increased resistance to nucleases.

The sequence information as provided herein should not be so narrowly construed as to require inclusion of erroneously identified bases. The specific sequences disclosed herein may be readily used to isolate the complete gene from a recombinant or non-recombinant microorganism capable of converting a given carbon source directly into Vitamin C, in particular *Gluconobacter oxydans*, preferably *Gluconobacter oxydans* DSM 17078 which in turn may easily be subjected to further sequence analyses thereby identifying sequencing errors.

Unless otherwise indicated, all nucleotide sequences determined by sequencing a DNA molecule herein were determined using an automated DNA sequencer and all amino acid sequences of polypeptides encoded by DNA molecules determined herein were predicted by translation of a DNA sequence determined as above. Therefore, as is known in the art for any DNA sequence determined by this automated approach, any nucleotide sequence determined herein may contain some errors. Nucleotide sequences determined by automation are typically at least about 90% identical, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of the sequenced DNA molecule. The actual sequence may be more precisely determined by other approaches including manual DNA sequencing methods well known in the art. As is also known in the art, a single insertion or deletion in a determined nucleotide sequence compared to the actual sequence will cause a frame shift in translation of the nucleotide sequence such that the predicted amino acid sequence encoded by a determined nucleotide sequence will be completely different from the amino acid sequence actually encoded by the sequenced DNA molecule, beginning at the point of such an insertion or deletion.

The person skilled in the art is capable of identifying such erroneously identified bases and knows how to correct for such errors.

A nucleic acid molecule according to the invention may comprise only a portion or a fragment of the nucleic acid sequence provided by the present invention, such as for instance the sequence shown in SEQ ID NO:1, for example a fragment which may be used as a probe or primer such as for instance SEQ ID NO:3 or SEQ ID NO:4 or a fragment encoding a portion of a protein according to the invention. The nucleotide sequence determined from the cloning of the STS 06 gene allows for the generation of probes and

primers designed for use in identifying and/or cloning other STS 06 family members, as well as STS 06 homologues from other species. The probe/primer typically comprises substantially purified oligonucleotides which typically comprises a region of nucleotide sequence that hybridizes preferably under highly stringent conditions to at least about 12 or 15, preferably about 18 or 20, more preferably about 22 or 25, even more preferably about 30, 35, 40, 45, 50, 55, 60, 65, or 75 or more consecutive nucleotides of a nucleotide sequence shown in SEQ ID NO:1 or a fragment or derivative thereof.

A nucleic acid molecule encompassing all or a portion of the nucleic acid sequence of SEQ ID NO:1 may be also isolated by the polymerase chain reaction (PCR) using synthetic oligonucleotide primers designed based upon the sequence information contained herein.

A nucleic acid of the invention may be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid thus amplified may be cloned into an appropriate vector and characterized by DNA sequence analysis.

Fragments of a polynucleotide according to the invention may also comprise polynucleotides not encoding functional polypeptides. Such polynucleotides may function as probes or primers for a PCR reaction.

Nucleic acids according to the invention irrespective of whether they encode functional or non-functional polypeptides, may be used as hybridization probes or polymerase chain reaction (PCR) primers. Uses of the nucleic acid molecules of the present invention that do not encode a polypeptide having a STS 06 activity include, inter alia, (1) isolating the gene encoding the protein of the present invention, or allelic variants thereof from a cDNA library, e.g., from other organisms than *Gluconobacter oxydans* and (2) Northern blot analysis for detecting expression of mRNA of said protein in specific cells or (3) use in enhancing and/or improving the function or activity of homologous STS 06 genes in said other organisms.

Probes based on the nucleotide sequences provided herein may be used to detect transcripts or genomic sequences encoding the same or homologous proteins for instance in other organisms. Nucleic acid molecules corresponding to natural variants and non-*G. oxydans* homologues of the *G. oxydans* STS 06 DNA of the invention which are also embraced by the present invention may be isolated based on their homology to the *G. oxydans* STS 06 nucleic acid disclosed herein using the *G. oxydans* DNA, or a portion thereof, as a hybridization probe according to standard hybridization techniques, preferably under highly stringent hybridization conditions.

In preferred embodiments, the probe further comprises a label group attached thereto, *e.g.*, the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme cofactor.

5 Homologous gene sequences may be isolated, for example, by performing PCR using two degenerate oligonucleotide primer pools designed on the basis of nucleotide sequences as taught herein.

The template for the reaction may be cDNA obtained by reverse transcription of mRNA prepared from strains known or suspected to express a polynucleotide according to the invention. The PCR product may be subcloned and sequenced to ensure that the amplified
10 sequences represent the sequences of a new nucleic acid sequence as described herein, or a functional equivalent thereof.

The PCR fragment may then be used to isolate a full length cDNA clone by a variety of known methods. For example, the amplified fragment may be labeled and used to screen a bacteriophage or cosmid cDNA library. Alternatively, the labeled fragment may be used
15 to screen a genomic library.

PCR technology can also be used to isolate full-length cDNA sequences from other organisms. For example, RNA may be isolated, following standard procedures, from an appropriate cellular or tissue source. A reverse transcription reaction may be performed on the RNA using an oligonucleotide primer specific for the most 5'-end of the amplified
20 fragment for the priming of first strand synthesis.

The resulting RNA/DNA hybrid may then be "tailed" (*e.g.*, with guanines) using a standard terminal transferase reaction, the hybrid may be digested with RNaseH, and second strand synthesis may then be primed (*e.g.*, with a poly-C primer). Thus, cDNA sequences upstream of the amplified fragment may easily be isolated. For a review of
25 useful cloning strategies, see *e.g.*, Sambrook et al., *supra*; and Ausubel et al., *supra*.

Also, nucleic acids encoding other STS 06 family members, which thus have a nucleotide sequence that differs from a nucleotide sequence according to SEQ ID NO:1, are within the scope of the invention. Moreover, nucleic acids encoding STS 06 proteins from different species which thus may have a nucleotide sequence which differs from a
30 nucleotide sequence shown in SEQ ID NO:1 are within the scope of the invention.

The invention also relates to an isolated polynucleotide hybridisable under stringent conditions, preferably under highly stringent conditions, to a polynucleotide as of the present invention, such as for instance a polynucleotide shown in SEQ ID NO:1.

Advantageously, such polynucleotide may be obtained from a microorganism capable of

converting a given carbon source directly into Vitamin C, in particular *Gluconobacter oxydans*, preferably *Gluconobacter oxydans* DSM 17078.

As used herein, the term "hybridizing" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least about 50%, at least about 60%, at
5 least about 70%, more preferably at least about 80%, even more preferably at least about 85% to 90%, most preferably at least 95% homologous to each other typically remain hybridized to each other.

In one embodiment, a nucleic acid of the invention is at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or
10 more homologous to a nucleic acid sequence shown in SEQ ID NO:1 or the complement thereof.

A preferred, non-limiting example of stringent hybridization conditions are hybridization in 6x sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 1x SSC, 0.1% SDS at 50°C, preferably at 55°C, more preferably at 60°C and
15 even more preferably at 65°C.

Highly stringent conditions include incubations at 42°C for a period of several days, such as 2-4 days, using a labeled DNA probe, such as a digoxigenin (DIG)-labeled DNA probe, followed by one or more washes in 2x SSC, 0.1% SDS at room temperature and one or more washes in 0.5x SSC, 0.1% SDS or 0.1x SSC, 0.1% SDS at 65-68°C. In particular,
20 highly stringent conditions include, for example, 2 h to 4 days incubation at 42°C using a DIG-labeled DNA probe (prepared by *e.g.* using a DIG labeling system; Roche Diagnostics GmbH, 68298 Mannheim, Germany) in a solution such as DigEasyHyb solution (Roche Diagnostics GmbH) with or without 100 µg/ml salmon sperm DNA, or a solution comprising 50% formamide, 5x SSC (150 mM NaCl, 15 mM trisodium citrate),
25 0.02% sodium dodecyl sulfate, 0.1% N-lauroylsarcosine, and 2% blocking reagent (Roche Diagnostics GmbH), followed by washing the filters twice for 5 to 15 minutes in 2x SSC and 0.1% SDS at room temperature and then washing twice for 15-30 minutes in 0.5x SSC and 0.1% SDS or 0.1x SSC and 0.1% SDS at 65-68°C.

Preferably, an isolated nucleic acid molecule of the invention that hybridizes under
30 preferably highly stringent conditions to a nucleotide sequence of the invention corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (*e.g.*, encodes a natural protein). In one embodiment, the nucleic acid encodes a natural *G. oxydans* STS 06 protein.

The skilled artisan will know which conditions to apply for stringent and highly stringent hybridization conditions. Additional guidance regarding such conditions is readily available in the art, for example, in Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, N. Y.; and Ausubel et al. (eds.), 1995, Current Protocols in Molecular Biology, (John Wiley & Sons, N. Y.). Of course, a polynucleotide which hybridizes only to a poly (A) sequence (such as the 3'-terminal poly (A) tract of mRNAs), or to a complementary stretch of T (or U) residues, would not be included in a polynucleotide of the invention used to specifically hybridize to a portion of a nucleic acid of the invention, since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (*e.g.*, practically any double-stranded cDNA clone).

In a typical approach, genomic DNA or cDNA libraries constructed from other organisms, *e.g.* microorganisms capable of converting a given carbon source directly into Vitamin C, in particular other *Gluconobacter* species may be screened.

For example, *Gluconobacter* strains may be screened for homologous polynucleotides by Southern and/or Northern blot analysis. Upon detection of transcripts homologous to polynucleotides according to the invention, DNA libraries may be constructed from RNA isolated from the appropriate strain, utilizing standard techniques well known to those of skill in the art. Alternatively, a total genomic DNA library may be screened using a probe hybridisable to a polynucleotide according to the invention.

A nucleic acid molecule of the present invention, such as for instance a nucleic acid molecule shown in SEQ ID NO:1 or a fragment or derivative thereof, may be isolated using standard molecular biology techniques and the sequence information provided herein. For example, using all or portion of the nucleic acid sequence shown in SEQ ID NO:1 as a hybridization probe, nucleic acid molecules according to the invention may be isolated using standard hybridization and cloning techniques (*e.g.*, as described in Sambrook, J., Fritsch, E. F. , and Maniatis, T. Molecular Cloning : A Laboratory Manual. 2nd, ed. , Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

Furthermore, oligonucleotides corresponding to or hybridisable to nucleotide sequences according to the invention may be prepared by standard synthetic techniques, *e.g.*, using an automated DNA synthesizer.

The terms "homology" or "percent identity" are used interchangeably herein. For the purpose of this invention, it is defined here that in order to determine the percent identity of two amino acid sequences or of two nucleic acid sequences, the sequences are aligned

- for optimal comparison purposes (*e.g.*, gaps may be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (*i.e.*, % identity = number of identical positions/total number of positions (*i.e.*, overlapping positions) x 100). Preferably, the two sequences are the same length.
- 10 The skilled person will be aware of the fact that several different computer programs are available to determine the homology between two sequences. For instance, a comparison of sequences and determination of percent identity between two sequences may be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and
- 15 Wunsch (J. Mol. Biol. (48): 444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at <http://www.accelrys.com>), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6 or 4 and a length weight of 1, 2, 3, 4, 5 or 6. The skilled person will appreciate that all these different parameters will yield slightly different results but that the overall
- 20 percentage identity of two sequences is not significantly altered when using different algorithms.

In yet another embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at <http://www.accelrys.com>), using a NWSgapdna.CMP matrix and a gap weight of 40, 50,

25 60, 70 or 80 and a length weight of 1, 2, 3, 4, 5 or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Meyers and W. Miller (CABIOS, 4: 11-17 (1989) which has been incorporated into the ALIGN program (version 2.0) (available at <http://vega.igh.cnrs.fr/bin/align-guess.cgi>) using a PAM120 weight residue table, a gap

30 length penalty of 12 and a gap penalty of 4.

The nucleic acid and protein sequences of the present invention may further be used as a "query sequence" to perform a search against public databases to, for example, identify other family members or related sequences. Such searches may be performed using the BLASTN and BLASTX programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol.

35 215:403-10. BLAST nucleotide searches may be performed with the BLASTN program, score = 100, word length = 12 to obtain nucleotide sequences homologous to the nucleic acid molecules of the present invention. BLAST protein searches may be performed with

the BLASTX program, score = 50, word length = 3 to obtain amino acid sequences homologous to the protein molecules of the present invention. To obtain gapped alignments for comparison purposes, Gapped BLAST may be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25 (17): 3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (*e.g.*,
5 BLASTX and BLASTN) may be used. See <http://www.ncbi.nlm.nih.gov>.

In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is the complement of a nucleotide sequence as of the present invention, such as for instance the sequence shown in SEQ ID NO:1. A
10 nucleic acid molecule, which is complementary to a nucleotide sequence disclosed herein, is one that is sufficiently complementary to a nucleotide sequence shown in SEQ ID NO:1 such that it may hybridize to said nucleotide sequence thereby forming a stable duplex.

In a further preferred embodiment, a nucleic acid of the invention as shown in SEQ ID NO:1 or the complement thereof contains at least one mutation leading to a gene product
15 with modified function/activity. The at least one mutation may be introduced by methods described herein. In one aspect, the at least one mutation leads to a STS 06 protein whose function compared to the wild type counterpart is completely or partially destroyed. Methods for introducing such mutations are well known in the art.

The term "reduction" of activity as used herein encompasses decreasing activity of one or
20 more polypeptides in the producing organism, which in turn are encoded by the corresponding polynucleotides described herein. There are a number of methods available in the art to accomplish reduction of activity of a given protein, in this case the STS 06 protein. In general, the specific activity of a protein may be decreased or the copy number of the protein may be decreased.

25 To facilitate such a decrease, the copy number of the genes corresponding to the polynucleotides described herein may be decreased, such as for instance by underexpression or disruption of a gene. A gene is said to be "underexpressed" if the level of transcription of said gene is reduced in comparison to the wild type gene. This may be measured by for instance Northern blot analysis quantifying the amount of mRNA as an
30 indication for gene expression. As used herein, a gene is underexpressed if the amount of generated mRNA is decreased by at least 1%, 2%, 5% 10%, 25%, 50%, 75%, 100%, 200% or even more than 500%, compared to the amount of mRNA generated from a wild-type gene. Alternatively, a weak promoter may be used to direct the expression of the polynucleotide. In another embodiment, the promoter, regulatory region and/or the
35 ribosome binding site upstream of the gene can be altered to achieve the down-expression. The expression may also be reduced by decreasing the relative half-life of the messenger

RNA. In another embodiment, the activity of the polypeptide itself may be decreased by employing one or more mutations in the polypeptide amino acid sequence, which decrease the activity. For example, altering the affinity of the polypeptide for its corresponding substrate may result in reduced activity. Likewise, the relative half-life of the polypeptide may be decreased. In either scenario, that being reduced gene expression or reduced activity, the reduction may be achieved by altering the composition of the cell culture media and/or methods used for culturing. "Reduced expression" or "reduced activity" as used herein means a decrease of at least 5%, 10%, 25%, 50%, 75%, 100%, 200% or even more than 500%, compared to a wild-type protein, polynucleotide, gene; or the activity and/or the concentration of the protein present before the polynucleotides or polypeptides are reduced. The activity of the STS 06 protein may also be reduced by contacting the protein with a specific or general inhibitor of its activity. The terms "reduced activity", "decreased or abolished activity" are used interchangeably herein.

Another aspect of the invention pertains to vectors, containing a nucleic acid encoding a protein according to the invention or a functional equivalent or portion thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments may be ligated. Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication). Other vectors are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome.

The recombinant vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vector includes one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operatively linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (*e.g.*, in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (*e.g.*, attenuator). Such regulatory sequences are described, for example, in Goeddel; Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive or inducible expression of a nucleotide sequence in many types of host cells and those which direct expression of the

- nucleotide sequence only in a certain host cell (*e.g.* tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention may be
- 5 introduced into host cells to thereby produce proteins or peptides, encoded by nucleic acids as described herein, including, but not limited to, mutant proteins, fragments thereof, variants or functional equivalents thereof, and fusion proteins, encoded by a nucleic acid as described herein, *e.g.*, STS 06 proteins, mutant forms of STS 06 proteins, fusion proteins and the like.
- 10 The recombinant expression vectors of the invention may be designed for expression of STS 06 proteins in a suitable microorganism. For example, a protein according to the invention may be expressed in bacterial cells such as strains belonging to the genera *Gluconobacter*, *Gluconacetobacter* or *Acetobacter*. Expression vectors useful in the present invention include chromosomal-, episomal- and virus-derived vectors *e.g.*, vectors
- 15 derived from bacterial plasmids, bacteriophage, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids.

The DNA insert may be operatively linked to an appropriate promoter, which may be either a constitutive or inducible promoter. The skilled person will know how to select

20 suitable promoters. The expression constructs may contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the mature transcripts expressed by the constructs may preferably include an initiation codon at the beginning and a termination codon appropriately positioned at the end of the polypeptide to be translated.

- 25 Vector DNA may be introduced into suitable host cells via conventional transformation or transfection techniques. As used herein, the terms "transformation", "transconjugation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (*e.g.*, DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, transduction,
- 30 infection, lipofection, cationic lipidmediated transfection or electroporation. Suitable methods for transforming or transfecting host cells may be found in Sambrook, et al. (*supra*), Davis et al., *Basic Methods in Molecular Biology* (1986) and other laboratory manuals.

- In order to identify and select cells which have integrated the foreign DNA into their
- 35 genome, a gene that encodes a selectable marker (*e.g.*, resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred

selectable markers include those that confer resistance to drugs, such as kanamycin, tetracycline, ampicillin and streptomycin. A nucleic acid encoding a selectable marker is preferably introduced into a host cell on the same vector as that encoding a protein according to the invention or can be introduced on a separate vector such as, for example, a suicide vector, which cannot replicate in the host cells. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (*e.g.*, cells that have incorporated the selectable marker gene will survive, while the other cells die).

The invention provides also an isolated polypeptide having the amino acid sequence shown in SEQ ID NO:2 or an amino acid sequence obtainable by expressing a polynucleotide of the present invention, such as for instance a polynucleotide sequence shown in SEQ ID NO:1 in an appropriate host.

Polypeptides according to the invention may contain only conservative substitutions of one or more amino acids in the amino acid sequence represented by SEQ ID NO:2 or substitutions, insertions or deletions of non-essential amino acids. Accordingly, a non-essential amino acid is a residue that may be altered in the amino acid sequences shown in SEQ ID NO:2 without substantially altering the biological function. For example, amino acid residues that are conserved among the proteins of the present invention, are predicted to be particularly unamenable to alteration. Furthermore, amino acids conserved among the proteins according to the present invention and other STS 06 proteins are not likely to be amenable to alteration.

The term "conservative substitution" is intended to mean that a substitution in which the amino acid residue is replaced with an amino acid residue having a similar side chain. These families are known in the art and include amino acids with basic side chains (*e.g.*, lysine, arginine and histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine).

As mentioned above, the polynucleotides of the invention may be utilized in the genetic engineering of a suitable host cell to make it better and more efficient in the fermentation, for example in a direct fermentation process for Vitamin C.

According to the invention a genetically engineered/recombinantly produced host cell (also referred to as recombinant cell or transformed cell) carrying such a modified polynucleotide wherein the function of the linked protein is significantly modified in comparison to a wild-type cell such that the yield, production and/or efficiency of

production of one or more fermentation products such as Vitamin C is improved. The host cell may be selected from a microorganism capable of directly producing one or more fermentation products such as for instance Vitamin C from a given carbon source, in particular *Gluconobacter oxydans*, preferably *G. oxydans* DSM 17078.

- 5 A "transformed cell" or "recombinant cell" is a cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a nucleic acid according to the invention, or wherein the activity of the STS 06 protein has been decreased or abolished. Suitable host cells include cells of microorganisms capable of producing a given fermentation product, *e.g.*, converting a given carbon source directly
10 into Vitamin C. In particular, these include strains from the genera *Pseudomonas*, *Pantoea*, *Escherichia*, *Corynebacterium*, *Ketogulonicigenium* and acetic acid bacteria like *e.g.*, *Gluconobacter*, *Acetobacter* or *Gluconacetobacter*, preferably *Acetobacter* sp., *Acetobacter aceti*, *Gluconobacter frateurii*, *Gluconobacter cerinus*, *Gluconobacter thailandicus*, *Gluconobacter oxydans*, more preferably *G. oxydans*, most preferably *G.*
15 *oxydans* DSM 17078.

- To improve the Vitamin C production of a certain recombinant host cell, STS 06 gene expression may be inhibited in that organism for instance by targeting nucleotide sequences complementary to the regulatory region of a STS 06 nucleotide sequence (*e.g.*, a STS 06 promoter and/or enhancers) to form triple helical structures that prevent
20 transcription of a STS 06 gene in target cells. See generally, Helene, C. (1991) *AnticancerDrugDes.* 6 (6): 569-84; Helene, C. et al. (1992) *Ann. N. Y Acad Sci.* 660: 27-36; and Maher, L. J. (1992) *Bioassays* 14 (12): 807-15.

- Inhibition or prevention of gene expression may also be achieved by modifying the STS 06 gene, *e.g.*, by introducing one or more mutations into the STS 06 gene wherein said
25 modification leads to a STS 06 protein with a function which is significantly decreased in comparison to the wild-type protein.

Therefore, in one other embodiment, the polynucleotide carrying the at least one mutation is derived from a polynucleotide as represented by SEQ ID NO:1 or equivalents thereof.

- A mutation as used herein may be any mutation leading to a less functional or unstable polypeptide, *e.g.* less functional or unstable STS 06 gene products. This may include for
30 instance an alteration in the genome of a microorganism, which interferes with the synthesis of STS 06 or leads to the expression of a STS 06 protein with an altered amino acid sequence whose function compared with the wild type counterpart having a non-altered amino acid sequence is completely or partially destroyed. The interference may
35 occur at the transcriptional, translational or post-translational level.

The alteration in the genome of the microorganism may be obtained *e.g.* by replacing through a single or double crossover-recombination a wild type DNA sequence by a DNA sequence containing the alteration. For convenient selection of transformants of the microorganism with the alteration in its genome the alteration may, *e.g.* be a DNA
5 sequence encoding an antibiotic resistance marker or a gene complementing a possible auxotrophy of the microorganism. Mutations include, but are not limited to, deletion-insertion mutations. An example of such an alteration includes a gene disruption, *i.e.* a perturbation of a gene such that the product that is normally produced from this gene is not produced in a functional form. This could be due to a complete deletion, a deletion and
10 insertion of a selective marker, an insertion of a selective marker, a frameshift mutation, an in-frame deletion, or a point mutation that leads to premature termination. In some of these cases the entire mRNA for the gene is absent, in others the amount of mRNA produced varies. In all cases the polypeptide encoded by said gene is not produced in a functional form, either absent or in a mutated form, such as *e.g.* a protein having reduced
15 activity as defined herein.

An alteration in the genome of the microorganism leading to a less or non-functional polypeptide may also be obtained by randomly mutagenizing the genome of the microorganism using *e.g.* chemical mutagens, radiation or transposons and selecting or
20 screening for mutants which are better or more efficient producers of one or more fermentation products. Standard methods for screening and selection are known to the skilled person.

In a specific embodiment, it is desired to knockout the STS 06 gene of the present invention, *i.e.*, wherein its gene expression is artificially suppressed in order to improve the yield, productivity, and/or efficiency of production of the fermentation product when
25 introduced into a suitable host cell. Methods of providing knockouts as well as microorganisms carrying such suppressed genes are well known in the art. The suppression of the endogenous STS 06 gene may be induced by deleting at least a part of the gene or the regulatory region thereof. As used herein, "suppression of the gene expression" includes complete and partial suppression, as well as suppression under
30 specific conditions and also suppression of the expression of either one of the two alleles.

In order to create a knockout microorganism in which the expression of the STS 06 gene is artificially suppressed, first the STS 06 gene may be cloned and then a vector for homologous recombination may be constructed by using the gene to inactivate the
endogenous STS 06 gene in the target microorganism. The vector for homologous
35 recombination then contains a nucleic acid sequence designed to inactivate the endogenous STS 06 gene in the target microorganism. Such a nucleic acid may be for instance a nucleic acid sequence of the STS 06 gene or the regulatory region thereof, such as the

existing flanking region of the gene to be inactivated (in cis), or existing separately (in trans), containing at least a partial deletion, or alternatively it may be a nucleic acid sequence of the STS 06 gene or the regulatory region thereof containing other genes. A gene which can also function as a marker is preferably selected as the gene to be inserted
5 into the STS 06 gene or the regulatory region thereof. The insert genes to be used include for instance drug-resistance genes as defined above. There is no particular limitation on the position where the genes may be inserted in the STS 06 gene, as long as the insertion at that position results in the suppression of the expression of the endogenous STS 06 gene in the target. To avoid polar effects of the insertion, in-frame silent deletions can be
10 introduced by using, for example, the sacB system or long-flanking homology PCR. These techniques are well known to the person skilled in the art.

The aforementioned mutagenesis strategies for STS 06 proteins may result in increased yields of a desired compound in particular Vitamin C. This list is not meant to be limiting; variations on these mutagenesis strategies will be readily apparent to one of ordinary skill
15 in the art. By these mechanisms, the nucleic acid and protein molecules of the invention may be utilized to generate microorganisms such as *Gluconobacter oxydans* or related strains of bacteria expressing mutated STS 06 nucleic acid and protein molecules such that the yield, productivity, and/or efficiency of production of a desired compound such as Vitamin C is improved.

20 In connection with the above process using a microorganism, in one aspect, the process of the present invention leads to yields of Vitamin C which are at least about more than 5.7 g/l, such as 10 g/l, 20 g/l, 50 g/l, 100 g/l, 200 g/l, 300 g/l, 400 g/l or more than 600 g/l. In one embodiment, the yield of Vitamin C produced by the process of the present invention is in the range of from about more than 5.7 to about 600 g/l. The yield of Vitamin C refers
25 to the concentration of Vitamin C in the harvest stream coming directly out of the production vessel, i.e. the cell-free supernatant comprising the Vitamin C.

In one aspect of the invention, microorganisms (in particular from the genera of *Gluconobacter*, *Gluconacetobacter* and *Acetobacter*) are provided that are able to directly produce Vitamin C from a suitable carbon source like D-sorbitol and/or L-sorbose. When
30 measured for instance in a resting cell method after an incubation period of 20 hours, these organisms were found to be able to produce Vitamin C directly from D-sorbitol or L-sorbose, even up to a level of 280 mg/l and 670 mg/l respectively. In another aspect of the invention, a microorganism is provided capable of directly producing Vitamin C in quantities of 300 mg/l when starting from D-sorbitol or more or 800 mg/l or more when
35 starting from L-sorbose, respectively when for instance measured in a resting cell method after an incubation period of 20 hours. Such may be achieved by decreasing or abolishing the activity of a STS polypeptide, preferably a STS 06 polypeptide. The yield of Vitamin

C produced from D-sorbitol may even be as high as 400, 600, 1000 mg/l or even exceed 1.5, 2, 4, 10, 20, 50 g/l. The yield of Vitamin C produced from L-sorbose may even be as high as 1000 mg/l or even exceed 1.5, 2, 4, 10, 20, 50 g/l. Preferably, these amounts of Vitamin C can be achieved when measured by resting cell method after an incubation
5 period of 20 hours.

As used herein, measurement in a "resting cell method" comprises (i) growing the cells by means of any method well known to the person skilled in the art, (ii) harvesting the cells from the growth broth, and (iii) incubating the harvested cells in a medium containing the substrate which is to be converted into the desired product, *e.g.* Vitamin C, under
10 conditions where the cells do not grow any longer, *i.e.* there is no increase in the amount of biomass during this so-called conversion step.

The recombinant microorganism carrying *e.g.* a modified STS 06 gene and which is able to produce the fermentation product in significantly higher yield, productivity, and/or efficiency may be cultured in an aqueous medium supplemented with appropriate nutrients
15 under aerobic conditions as described above.

The nucleic acid molecules, polypeptides, vectors, primers, and recombinant microorganisms described herein may be used in one or more of the following methods: identification of *Gluconobacter oxydans* and related organisms; mapping of genomes of organisms related to *Gluconobacter oxydans*; identification and localization of
20 *Gluconobacter oxydans* sequences of interest; evolutionary studies; determination of STS 06 protein regions required for function; modulation of a STS 06 protein activity or function; modulation of the activity of a STS pathway; and modulation of cellular production of a desired compound, such as Vitamin C.

The invention provides methods for screening molecules which modulate the activity of a
25 STS 06 protein, either by interacting with the protein itself or a substrate or binding partner of the STS 06 protein, or by modulating the transcription or translation of a STS 06 nucleic acid molecule of the invention. In such methods, a microorganism expressing one or more STS 06 proteins of the invention is contacted with one or more test compounds, and the effect of each test compound on the activity or level of expression of the STS 06 protein is
30 assessed.

The biological, enzymatic or other activity of STS proteins can be measured by methods well known to a skilled person, such as, for example, by incubating a membrane fraction containing the STS protein with the radioactively marked sugar or sugar alcohol which can be actively transported by the STS protein. The incorporation of radioactivity into the cell
35 mass is directly proportional to the activity of the transporter. Thus, for example, the

activity of a transporter can be measured in an assay where intact cells containing the specific transporter are incubated in the presence of phosphate buffer at pH 6 and the radioactively marked carbon source such as *e.g.* glucose. The rate of assimilation of radioactive carbon source such as *e.g.* glucose by the cells can be measured by methods
5 known to the skilled person, and is directly proportional to the STS protein activity present in the membrane fraction.

It may be evident from the above description that the fermentation product of the methods according to the invention may not be limited to Vitamin C alone. The "desired compound" or "fermentation product" as used herein may be any natural product of
10 *Gluconobacter oxydans*, which includes the final products and intermediates of biosynthesis pathways, such as for example L-sorbose, L-sorbose, D-gluconate, 2-keto-D-gluconate, 5-keto-D-gluconate, 2,5-diketo-D-gluconate and 2-keto-L-gulonate (2-KGA), in particular the biosynthetic generation of Vitamin C.

Thus, the present invention is directed to the use of a polynucleotide, polypeptide, vector,
15 primer and recombinant microorganism as described herein in the production of Vitamin C, *i.e.*, the direct conversion of a carbon source into Vitamin C. In a preferred embodiment, a modified polynucleotide, polypeptide, vector and recombinant microorganism as described herein is used for improving the yield, productivity, and/or efficiency of the production of Vitamin C.

20 The terms "production" or "productivity" are art-recognized and include the concentration of the fermentation product (for example, Vitamin C) formed within a given time and a given fermentation volume (*e.g.*, kg product per hour per liter). The term "efficiency of production" includes the time required for a particular level of production to be achieved (for example, how long it takes for the cell to attain a particular rate of output of a
25 fermentation product). The term "yield" is art-recognized and includes the efficiency of the conversion of the carbon source into the product (*i.e.*, Vitamin C). This is generally written as, for example, kg product per kg carbon source. By "increasing the yield and/or production/productivity" of the compound it is meant that the quantity of recovered molecules, or of useful recovered molecules of that compound in a given amount of
30 culture over a given amount of time is increased. The terms "biosynthesis" or a "biosynthetic pathway" are art-recognized and include the synthesis of a compound, preferably an organic compound, by a cell from intermediate compounds in what may be a multistep and highly regulated process. The language "metabolism" is art-recognized and includes the totality of the biochemical reactions that take place in an organism. The
35 metabolism of a particular compound, then, (*e.g.*, the metabolism of an amino acid such as glycine) comprises the overall biosynthetic, modification, and degradation pathways in the cell related to this compound. The language "transport" or "import" is art-recognized and

includes the facilitated movement of one or more molecules across a cellular membrane through which the molecule would otherwise either be unable to pass or be passed inefficiently.

Vitamin C as used herein may be any chemical form of L-ascorbic acid found in aqueous solutions, such as for instance undissociated, in its free acid form or dissociated as an anion. The solubilized salt form of L-ascorbic acid may be characterized as the anion in the presence of any kind of cations usually found in fermentation supernatants, such as for instance potassium, sodium, ammonium, or calcium. Also included may be isolated crystals of the free acid form of L-ascorbic acid. On the other hand, isolated crystals of a salt form of L-ascorbic acid are called by their corresponding salt name, *i.e.* sodium ascorbate, potassium ascorbate, calcium ascorbate and the like.

In one preferred embodiment, the present invention is related to a process for the production of Vitamin C wherein a nucleotide according to the invention or a modified polynucleotide sequence as described above is introduced into a suitable microorganism, the recombinant microorganism is cultured under conditions that allow the production of Vitamin C in high productivity, yield, and/or efficiency, the produced fermentation product is isolated from the culture medium and optionally further purified.

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patent applications, patents and published patent applications, cited throughout this application are hereby incorporated by reference.

Examples

Example 1: Preparation of chromosomal DNA and amplification of DNA fragment by PCR

Chromosomal DNA of *Gluconobacter oxydans* DSM 17078 was prepared from the cells cultivated at 30°C for 1 day in mannitol broth (MB) liquid medium consisting of 25 g/l mannitol, 5 g/l of yeast extract (Difco), and 3 g/l of Bactopeptone (Difco) by the method described by Sambrook et al (1989) "Molecular Cloning: A Laboratory Manual/Second Edition", Cold Spring Harbor Laboratory Press).

A DNA fragment was prepared by PCR with the chromosomal DNA prepared above and a set of primers, Pf (SEQ ID NO:3) and Pr (SEQ ID NO:4). For the reaction, the Expand High Fidelity PCR kit (Roche Diagnostics) and 10 ng of the chromosomal DNA was used in total volume of 100 µl according to the supplier's instruction to have the PCR product

containing STS 06 DNA sequence (SEQ ID NO:1). The PCR product was recovered from the reaction and its correct sequence confirmed.

Example 2: Disruption of the STS 06 gene in *G. oxydans* DSM 17078

In order to construct a knockout mutant of the STS 06 gene, Long-Flanking Homology (LFH) PCR was used to construct a clean deletion-insertion mutation. Firstly, the upstream and downstream regions flanking the STS 06 gene were amplified by PCR using the respective primer pairs STS 06LFH+1 (SEQ ID NO:5) / STS 06KmLFH-1 (SEQ ID NO:6) containing complementary kanamycin-resistance cassette overhang at 5'-end and STS 06KmLFH+1 (SEQ ID NO:7) containing complementary kanamycin-resistance cassette overhang at 5'-end / STS 06LFH-1 (SEQ ID NO:8) to obtain approximately 550-bp products. *G. oxydans* DSM 17078 genomic DNA was used as a template and the reaction conditions consisted of 35 cycles of denaturation at 94°C for 30 sec, annealing at 50°C for 30 sec and extension at 72°C for 1 min. In both cases, the GC-rich PCR kit (Roche Molecular Biochemicals) was used to minimize PCR-generated errors. The kanamycin-resistance cassette was amplified using plasmid pUC4K (Amersham Bioscience, accession No. X06404) as a template and primer pair Km+1 (SEQ ID NO:9) / Km-1 (SEQ ID NO:10) to generate a 1.3-kb fragment. The reaction conditions were as above. The three products were gel-purified, mixed and used in the second round PCR reaction with the flanking primers STS 06LFH+1 / STS 06LFH-1 to generate a product of 2.4-kb. The reaction conditions for the second round reaction consisted of 94°C, 2 min, then 10 cycles of [94°C, 30 sec, 63°C, 30 sec, 68°C, 6 min], followed by 20 cycles of [94°C, 30 sec, 63°C, 30 sec, 68°C, 6 min with an additional 20 sec per cycle] and a final extension at 68°C for 10 min.

The PCR product was cloned into the pGEM-TEasy vector (Promega Corp.) to give plasmid pGEM-STS 06. This plasmid was transformed into competent *G. oxydans* DSM 17078 cells selecting transformants on MB agar medium containing kanamycin to a final concentration of 50 µg ml⁻¹. Several putative transformants were observed of which two were analyzed by PCR using the flanking primers STS 06LFH+1 / STS 06LFH-1 to verify that the STS 06::Km mutation had integrated *via* a double crossover. Both strains carrying the mutation were named *G. oxydans* DSM 17078-STS 06::Km1 and *G. oxydans* DSM 17078-STS 06::Km2.

Example 3: Production of Vitamin C from D-sorbitol using resting cells

Cells of *G. oxydans* DSM 17078, *G. oxydans* DSM 17078-STS 06::Km1 and *G. oxydans* DSM 17078-STS 06::Km2 were grown at 27°C for 3 days on No. 3BD agar medium

- 36 -

containing 70 g/l D-sorbitol, 0.5 g/l glycerol, 7.5 g/l yeast extract (Difco), 2.5 g/l $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 10 g/l CaCO_3 and 18 g/l agar (Difco).

Cells were scraped from the agar plates, suspended in distilled water and used for resting cell reactions conducted at 30°C with shaking at 220 rpm. A series of reactions (0.5 ml reaction mixture in 5 ml reaction tubes) was carried out with 2% D-sorbitol in reaction mixtures further containing 0.3% NaCl, and 1% CaCO_3 and was incubated with cells at a final concentration of $\text{OD}_{600} = 10$. After an incubation period of 20 hours, samples of the reaction mixtures were analyzed by high performance liquid chromatography (HPLC) using an Agilent 1100 HPLC system (Agilent Technologies, Wilmington, USA) with a LiChrospher-100-RP18 (125 x 4.6 mm) column (Merck, Darmstadt, Germany) attached to an Aminex-HPX-78H (300 x 7.8 mm) column (Biorad, Reinach, Switzerland). The mobile phase was 0.004 M sulfuric acid, and the flow rate was 0.6 ml/min. Two signals were recorded using an UV detector (wavelength 254 nm) in combination with a refractive index detector. In addition, the identification of the L-ascorbic acid was done using an amino-column (YMC-Pack Polyamine-II, YMC, Inc., Kyoto, Japan) with UV detection at 254 nm. The mobile phase was 50 mM $\text{NH}_4\text{H}_2\text{PO}_4$ and acetonitrile (40:60).

An Agilent Series 1100 HPLC-mass spectrometry (MS) system was used to identify L-ascorbic acid. The MS was operated in positive ion mode using the electrospray interface. The separation was carried out using a LUNA-C8(2) column (100 x 4.6 mm) (Phenomenex, Torrance, USA). The mobile phase was a mixture of 0.1% formic acid and methanol (96:4). L-Ascorbic acid eluted with a retention time of 3.1 minutes. The identity of the L-ascorbic acid was confirmed by retention time and the molecular mass of the compound.

The *G. oxydans* DSM 17078-STS 06::Km1 and *G. oxydans* DSM 17078-STS 06::Km2 mutant strains were able to produce 890 mg/l Vitamin C compared to 750 mg/l for strain *G. oxydans* DSM 17078, an approximate increase in Vitamin C production of 20%.

Example 4: Presence of the STS 06 gene and equivalents in other organisms

The presence of SEQ ID NO:1 and/or equivalents showing similarity/identity to SEQ ID NO:1 in other organisms than the ones disclosed herein before, e.g. organisms as mentioned in Table 1, may be determined by a simple DNA hybridization experiment.

Strains of *Acetobacter aceti* subsp. *xylinum* IFO 13693 and IFO 13773 are grown at 27°C for 3 days on No. 350 medium containing 5 g/l Bactopeptone (Difco), 5 g/l yeast extract (Difco), 5 g/l glucose, 5 g/l mannitol, 1 g/l $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 5 ml/l ethanol, and 15 g/l agar. All other *Acetobacter*, *Gluconacetobacter* and all *Gluconobacter* strains are grown at 27°C for 3 days on mannitol broth (MB) agar medium containing 25 g/l mannitol, 5 g/l yeast

extract (Difco), 3 g/l Bactopeptone (Difco), and 18 g/l agar (Difco). *E. coli* K-12 is grown on Luria Broth agar medium. The other strains/cells are grown on medium recommended by the suppliers or according to methods known in the art. Genomic DNA is extracted as described by *e.g.* Sambrook *et al.*, 1989, "Molecular Cloning: A Laboratory
5 Manual/Second Edition", Cold Spring Harbor Laboratory Press) from a suitable organism as *e.g.* mentioned in Table 1.

Genomic DNA preparations are digested with restriction enzymes such as *Eco*RI or *Hind*III, and 1 μ g of the DNA fragments are separated by agarose gel electrophoresis (1% agarose). The gel is treated with 0.25 N HCl for 15 min and then 0.5 N NaOH for 30 min,
10 and then blotted onto nitrocellulose or a nylon membrane with Vacuum Blotter Model 785 (BIO-RAD Laboratories AG, Switzerland) according to the instruction of the supplier. The resulting blot is then brought into contact/hybridized with a solution wherein the probe, such as *e.g.* a DNA fragment with SEQ ID NO:1 sequence or a DNA fragment containing the part or whole of the SEQ ID NO:1 sequence to detect positive DNA
15 fragment(s) from a test organism. A DIG-labeled probe, *e.g.* SEQ ID NO:1, may be prepared according to Example 1 by using the PCR-DIG labeling kit (Roche Diagnostics) and a set of primers, SEQ ID NO:3 and SEQ ID NO:4. A result of such a blot is depicted in Table 1.

The hybridization may be performed under stringent or highly stringent conditions. A
20 preferred, non-limiting example of such conditions are hybridization in 6x sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 1x SSC, 0.1% SDS at 50°C, preferably at 55°C, more preferably at 60°C and even more preferably at 65°C. Highly stringent conditions include, for example, 2 h to 4 days incubation at 42°C in a solution such as DigEasyHyb solution (Roche Diagnostics GmbH) with or
25 without 100 μ g/ml salmon sperm DNA, or a solution comprising 50% formamide, 5x SSC (150 mM NaCl, 15 mM trisodium citrate), 0.02% sodium dodecyl sulfate, 0.1% N-lauroylsarcosine, and 2% blocking reagent (Roche Diagnostics GmbH), followed by washing the filters twice for 5 to 15 min in 2x SSC and 0.1% SDS at room temperature and then washing twice for 15-30 min in 0.5x SSC and 0.1% SDS or 0.1x SSC and 0.1%
30 SDS at 65-68°C. To detect DNA fragments with lower identity to the probe DNA, final washing steps can be done at lower temperatures such as 50-65°C and for shorter washing time such as 1-15 min.

The genes corresponding to the positive signals within the respective organisms shown in Table 1 can be cloned by a PCR method well known in the art using genomic DNA of
35 such an organism together with a suitable primer set, such as *e.g.* SEQ ID NO:3 and SEQ ID NO:4 under conditions as described in Example 1 or as follows: 5 to 100 ng of genomic DNA is used per reaction (total volume 50 μ l). Expand High Fidelity PCR system (Roche

Diagnostics) can be used with reaction conditions consisting of 94°C for 2 min; 30 cycles of (i) denaturation step at 94°C for 15 sec, (ii) annealing step at 60°C for 30 sec, (iii) synthesis step at 72°C for 0.5 to 5 min depending to the target DNA length (1 min /1 kb); extension at 72°C for 7 min. Alternatively, one can perform a PCR with degenerate
 5 primers, which can be synthesized based on SEQ ID NO:2 or amino acid sequences as consensus sequences selected by aligning several amino acid sequences obtained by a sequence search program such as BLASTP (or BLASTX when nucleotide sequence is used as a "query sequence") to find proteins having a similarity to the protein of SEQ ID NO:2. For PCR using degenerate primers, temperature of the second annealing step (see
 10 above) can be lowered to 55°C, or even to 50-45°C. A result of such an experiment is shown in Table 1.

Samples of the PCR reactions are separated by agarose gel electrophoresis and the bands are visualized with a transilluminator after staining with *e.g.* ethidium bromide, isolated from the gel and the correct sequence is confirmed.

15 Consensus sequences mentioned above might be amino acid sequences belonging to certain categories of several protein domain/family databases such as PROSITE (database of protein families and domains), COGs (Cluster of Ortholog Groups), CDD (Conserved Domain Databases), pfam (large collection of multiple sequence alignments and hidden Markov models covering many common protein domains and families). Once one can
 20 select certain protein with identical/similar function to the protein of this invention from proteins containing domain or family of such databases, corresponding DNA encoding the protein can be amplified by PCR using the protein sequence or its nucleotide sequence when it is available in public databases.

25 **Example 5: Disruption of the STS 06 gene and equivalents in other organisms for production of Vitamin C**

In order to improve Vitamin C production in a suitable microorganism which is capable to directly produce Vitamin C from a given substrate, the STS 06 gene and equivalents as *e.g.* a PCR product obtained in Example 4, referred to hereafter as gene X, can be disrupted in accordance to the STS 06 gene in *G. oxydans* DSM 17078 (see Example 2) to generate a
 30 knockout mutant carrying STS 06 equivalent gene::Km. Suitable host strains for generation of such knockout mutants may be selected from *e.g.* *Gluconobacter* strains listed in Table 1, in particular *e.g.* *G. oxydans* IFO 3293, *G. oxydans* IFO 3292, *G. oxydans* ATCC 621H, *G. oxydans* IFO 12528, *G. oxydans* IFO 3291, *G. oxydans* IFO 3255, *G. oxydans* IFO 3244, *G. cerinus* IFO 3266, *G. frateurii* IFO 3260, *G. oxydans* IFO 3287,
 35 *Acetobacter aceti subsp. orleanus* IFO 3259, *Acetobacter aceti subsp. xylinum* IFO 13693, *Acetobacter aceti subsp. xylinum* IFO 13773 and *Acetobacter sp.* ATCC 15164.

The knockout mutant such as, e.g. a knockout mutant *G. oxydans* IFO 3293-STS 06 equivalent gene::Km can be generated as follows: the PCR product obtained in Example 4 is cloned in an *E. coli* vector pCR2.1-TOPO and used to transform *E. coli* TG1 to have a Apr transformant carrying pCR2.1-gene X. Then, Kmr cassette isolated from pUC-4K (Amersham Bioscience, accession No. X06404) is inserted into one of the restriction site of the target gene with ligase and the resulting ligation product is used to transform *E. coli* TG1 to have Apr Kmr transformant carrying pCR2.1-gene X::Km. The pCR2.1-gene X::Km plasmid prepared from the transformant is digested by two restriction enzymes selected from the multi-cloning site of the vector part to isolate a DNA fragment containing gene X::Km. The resulting DNA fragment is used to transform the host strain carrying the STS 06 equivalent gene by electroporation to have the gene disruptant carrying STS 06 equivalent gene::Km.

Further modifications including genes involved in the conversion of D-sorbitol, L-sorbose and/or L-sorbose into Vitamin C within said strains may be generated to improve Vitamin C production by such strains.

Production of Vitamin C using the cells of the knockout mutant, e.g. *G. oxydans* IFO 3293-STS 06 equivalent gene::Km, and the corresponding wild-type strain, e.g. *G. oxydans* IFO 3293, are performed according to Example 3.

In the resting cell reaction with 1% L-sorbose as the substrate, the mutant strain can produce at least more than 20% Vitamin C compared to the wild-type strain.

Table 1: Equivalents of the STS 06 gene in other organisms.

Strain	Signal 1	Signal 2	Signal 3
<i>G. oxydans</i> DSM 17078	+	+	+
<i>G. oxydans</i> IFO 3293	+	+	+
<i>G. oxydans</i> IFO 3292	+	+	+
<i>G. oxydans</i> ATCC 621H	+	+	+
<i>G. oxydans</i> IFO 12528	+	+	+
<i>G. oxydans</i> G 624	+	+	+
<i>G. oxydans</i> T-100	+	+	+
<i>G. oxydans</i> IFO 3291	+	+	+
<i>G. oxydans</i> IFO 3255	+	+	+
<i>G. oxydans</i> ATCC 9937	+	+	+
<i>G. oxydans</i> IFO 3244	+	+	+
<i>G. cerinus</i> IFO 3266	+	+	+

- 40 -

<i>G. frateurii</i> IFO 3260	+	+	+
<i>G. oxydans</i> IFO 3287	+	+	+
<i>Acetobacter aceti</i> subsp. <i>orleanus</i> IFO 3259	+	+	+
<i>Acetobacter aceti</i> subsp. <i>xylinum</i> IFO 13693	+	+	+
<i>Acetobacter aceti</i> subsp. <i>xylinum</i> IFO 13773	+	+	+
<i>Acetobacter</i> sp. ATCC 15164	+	+	+
<i>G. thailandicus</i> NBRC 100600	+	+	+
<i>Gluconacetobacter liquefaciens</i> ATCC 14835	+	+	+
<i>Gluconacetobacter polyoxogenes</i> NBI 1028	+	+	+
<i>Gluconacetobacter diazotrophicus</i> ATCC 49037	+	+	+
<i>Gluconacetobacter europaeus</i> DSM 6160	+	+	+
<i>Acetobacter aceti</i> 1023	-	-	+
<i>Acetobacter pasteurianus</i> NCI 1193	-	-	+
<i>Pseudomonas putida</i> ATCC 21812	-	-	+
<i>Pseudomonas aeruginosa</i> PAO1	-	-	+
<i>Pseudomonas fluorescens</i> DSM 50106	-	-	+
<i>Pseudomonas syringae</i> B728a	-	-	+
<i>Paracoccus denitrificans</i> strain Pd1222	-	-	+
<i>Rhodopseudomonas palustris</i> CGA009	-	-	+
<i>E. coli</i>	-	-	-
<i>Saccharomyces cerevisiae</i>	-	-	-
<i>Aspergillus niger</i>	-	-	-
Mouse	-	-	-

Signal 1: Detection of DNA on a blot with genomic DNA of different strains and SEQ ID NO:1 as labeled probe. Signal 2: Detection of DNA of different strains in a PCR reaction using primer pair SEQ ID NO:3 and SEQ ID NO:4. Signal 3: Detection of DNA of different strains in a PCR reaction using degenerate primers. For more explanation refer to the text.

Claims

1. A polynucleotide selected from the group consisting of:
 - (a) polynucleotides encoding a polypeptide comprising the amino acid sequence according to SEQ ID NO:2;
 - 5 (b) polynucleotides comprising the nucleotide sequence according to SEQ ID NO:1;
 - (c) polynucleotides comprising a nucleotide sequence obtainable by nucleic acid amplification such as polymerase chain reaction, using genomic DNA from a microorganism as a template and a primer set according to SEQ ID NO:3 and SEQ ID NO:4;
 - 10 (d) polynucleotides comprising a nucleotide sequence encoding a fragment or derivative of a polypeptide encoded by a polynucleotide of any of (a) to (c) wherein in said derivative one or more amino acid residues are conservatively substituted compared to said polypeptide, and said fragment or derivative has the activity of a sugar transporter and/or sugar alcohol transporter;
 - 15 (e) polynucleotides the complementary strand of which hybridizes under stringent conditions to a polynucleotide as defined in any one of (a) to (d) and which encode a sugar transporter and/or sugar alcohol transporter; and
 - (f) polynucleotides which are at least 70%, such as 85, 90 or 95% identical to a polynucleotide as defined in any one of (a) to (d) and which encode a sugar transporter
20 and/or sugar alcohol transporter
- or
- the complementary strand of such a polynucleotide.
2. A vector containing the polynucleotide according to claim 1.
3. The vector of claim 2 in which the polynucleotide is operatively linked to expression
25 control sequences allowing the expression in prokaryotic or eukaryotic host cells.
4. A microorganism genetically engineered with a polynucleotide according to claim 1 or with the vector of claim 2 or 3.

5. A microorganism according to claim 4 capable of directly producing Vitamin C from D-sorbitol in quantities of 300 mg/l or more when measured in a resting cell method after an incubation period of 20 hours.
6. A microorganism according to claim 5 capable of directly producing Vitamin C from L-sorbose in quantities of 800 mg/l or more.
7. A polypeptide encoded by a polynucleotide according to claim 1.
8. Process for producing cells capable of expressing a polypeptide according to claim 7, comprising the step of genetically engineering cells with the vector of claim 2 or 3 or with a polynucleotide according to claim 1.
9. Use of a disrupted polynucleotide according to claim 1 for the production of Vitamin C.
10. A microorganism according to claim 4 or a microorganism containing an endogenous gene comprising a polynucleotide according to claim 1, said microorganism being genetically altered in such a way that it leads to an improved yield and/or efficiency of production of Vitamin C produced by said microorganism.
11. A microorganism according to claim 10 producing a polypeptide according to claim 7 with decreased or abolished sugar transporter and/or sugar alcohol transporter activity.
12. A microorganism according to any one of claims 4 to 6, 10 or 11 wherein the polynucleotide according to claim 1 is disrupted.
13. A microorganism according to any one of claim 4 to 6 or 10 to 12 selected from the group consisting of *Pseudomonas*, *Pantoea*, *Escherichia*, *Corynebacterium*, *Ketogulonicigenium* and acetic acid bacteria like e.g., *Gluconobacter*, *Acetobacter* or *Gluconacetobacter*, preferably *Acetobacter* sp., *Acetobacter aceti*, *Gluconobacter frateurii*, *Gluconobacter cerinus*, *Gluconobacter thailandicus*, *Gluconobacter oxydans*, preferably *Gluconobacter oxydans*, more preferably *Gluconobacter oxydans* DSM 17078.
14. Process for the production of an disrupted endogenous sugar transporter and/or sugar alcohol transporter gene in a microorganism, said microorganism comprising a polynucleotide according to claim 1, said process comprising the step of altering said polynucleotide in such a way that it leads to an improved yield and/or efficiency of production of Vitamin C produced by said microorganism.
15. Process for the production of a microorganism capable of producing Vitamin C, comprising the step of altering said microorganism so that the microorganism produces a

polypeptide with reduced or abolished sugar transporter and/or sugar alcohol transporter activity leading to an improved yield and/or efficiency of production of Vitamin C produced by said microorganism.

16. Process for the production of a microorganism containing an endogenous gene
5 comprising a polynucleotide according to claim 1, comprising the step of altering said microorganism so that the endogenous gene is underexpressed or disrupted, leading to an improved yield and/or efficiency of production of Vitamin C produced by said microorganism.
17. Process according to claim 15 or 16 for the production of a microorganism according
10 to any one of claims 10 to 13.
18. Microorganism obtainable by a process according to any one of claims 14 to 16.
19. Process for the production of Vitamin C with a microorganism according to any one
of claims 10 to 13 or claims 4 to 6 wherein said microorganism is cultivated in a aqueous nutrient medium under conditions that allow the direct production of Vitamin C from D-
15 sorbitol or L-sorbose and wherein optionally Vitamin C is isolated as the fermentation product.

- 1 -

SEQUENCE LISTING

5 <110> DSM IP Assets B.V.
 <120> Novel Gene STS 06
 <130> 24585
 10 <160> 10
 <170> PatentIn version 3.2
 <210> 1
 15 <211> 828
 <212> DNA
 <213> Gluconobacter oxydans DSM 17078
 <400> 1
 20 gtgagactca caacagagat gctggtcaca ggacgtctgg tcgcgatggc cttcatcatc 60
 ctacacacgc tgtttccact ctactgggcg ctcgtcacgt cattccgtca cggaaccaca 120
 cttttttcca cagccctctt cacgttcccc gaccttgaaa actaccgaaa agtcctcggc 180
 25 ggtccagaac tgtggcgga gacgttcaac tcggtcctgt gcgcgggttc cgttacgctc 240
 ctctcgctcc tcctcggcatt tccggcagcc tatgccctcg gtcagatgag tttcccggg 300
 30 cgcgggctgg tgcttggcat cctgctgctc tgctcgatgc tgcccagat cgccatcctg 360
 tccggcctgt tcgaactgat ctgggccatg gggctgtatg atcacgttga aagcatcatt 420
 ttgcgcgacc tgttctttgc ccttcccttc acgatctggg tattgacggg tttttccgg 480
 35 gacctcccc ccgaactgga cgacgcggca aaactggacg gctgcagcct gatgcgccg 540
 atcttcagca ttcacctgcc cctggctctg cgggaattg ccgccacggg actgctgaat 600
 40 atcatgacat gctggaacga gtttcttttt gccctgacct tcacactcaa cgactcagcc 660
 cgtacccttc cggtcggtat cggactgatt tccgctccag gccggtttga acttcctttc 720
 45 gggaccatca tggccgcata ccttctcgca accctcccc cgatcctgct cgtcctgttc 780
 ttccagaacc gcattgcctc cggcctgact gcgggggctg tcaaatga 828
 <210> 2
 50 <211> 275
 <212> PRT
 <213> Gluconobacter oxydans DSM 17078
 <400> 2
 55 Val Arg Leu Thr Thr Glu Met Leu Val Thr Gly Arg Leu Val Ala Met
 1 5 10 15

[illegible]

- 4 -

<212> DNA
<213> Artificial

<220>
5 <223> primer

<400> 7
cagagatttt gagacacaac gtggcctgtc aaatgaacga aaacacccg 49

10
<210> 8
<211> 21
<212> DNA
<213> Artificial

15
<220>
<223> primer

<400> 8
20 cacgtcaaag ccacgccaca g 21

<210> 9
<211> 25
25 <212> DNA
<213> Artificial

<220>
<223> primer

30
<400> 9
gccacgttgt gtctcaaaat ctctg 25

35 <210> 10
<211> 21
<212> DNA
<213> Artificial

40 <220>
<223> primer

<400> 10
45 ggcgctgagg tctgcctcgt g 21

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: N44-1	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: DSM 17078
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I. above was accompanied by: ☐ a scientific description ☒ a proposed taxonomic designation (Mark with a cross where applicable).	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on 2005-01-26 (Date of the original deposit) ¹ .	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on _____ (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on _____ (date of receipt of request for conversion).	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: 2005-01-28

¹ Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired.

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

VIABILITY STATEMENT
issued pursuant to Rule 10.2 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. DEPOSITOR Name: DSM IP Assets B.V. Het Overloon 1 Address: NL-6411 TE Heerlen	II. IDENTIFICATION OF THE MICROORGANISM Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: DSM 17078 Date of the deposit or the transfer ¹ : 2005-01-26
III. VIABILITY STATEMENT The viability of the microorganism identified under II above was tested on 2005-01-26 ² . On that date, the said microorganism was ☒ ³ viable ☐ ³ no longer viable	
IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED⁴ 	
V. INTERNATIONAL DEPOSITARY AUTHORITY Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Address: Mascheroder Weg 1b D-38124 Braunschweig Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: 2005-01-28	

¹ Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).

² In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test.

³ Mark with a cross the applicable box.

⁴ Fill in if the information has been requested and if the results of the test were negative.